Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,800 | 2019-12-04 00:00:00 UTC | Here's Why Revance Therapeutics Stock Is Falling Today | ABBV | https://www.nasdaq.com/articles/heres-why-revance-therapeutics-stock-is-falling-today-2019-12-04 | null | null | What happened
Shares of Revance Therapeutics (NASDAQ: RVNC) are under pressure after management announced the pricing of a secondary offering. Investors dismayed by the pricing of the offering have hammered the biotech stock 16.4% lower as of 12:07 p.m. EST on Wednesday.
So what
Revance shares had been climbing since t... | That means Revance could end up competing with AbbVie (NYSE: ABBV) for a slice of Botox sales, which have risen to around $2.7 billion annually. If Mylan agrees to launch DAXI and give Revance a mid-double-digit royalty percentage on future sales, it could get much harder for AbbVie's acquisition of Allergan to deliver... | That means Revance could end up competing with AbbVie (NYSE: ABBV) for a slice of Botox sales, which have risen to around $2.7 billion annually. If Mylan agrees to launch DAXI and give Revance a mid-double-digit royalty percentage on future sales, it could get much harder for AbbVie's acquisition of Allergan to deliver... | That means Revance could end up competing with AbbVie (NYSE: ABBV) for a slice of Botox sales, which have risen to around $2.7 billion annually. If Mylan agrees to launch DAXI and give Revance a mid-double-digit royalty percentage on future sales, it could get much harder for AbbVie's acquisition of Allergan to deliver... | That means Revance could end up competing with AbbVie (NYSE: ABBV) for a slice of Botox sales, which have risen to around $2.7 billion annually. If Mylan agrees to launch DAXI and give Revance a mid-double-digit royalty percentage on future sales, it could get much harder for AbbVie's acquisition of Allergan to deliver... |
24,801 | 2019-12-03 00:00:00 UTC | Despite the Naysayers, AbbVie Keeps Marching On | ABBV | https://www.nasdaq.com/articles/despite-the-naysayers-abbvie-keeps-marching-on-2019-12-03 | null | null | AbbVie's (NYSE: ABBV) story in recent years is familiar to those who follow the pharmaceutical industry. The company's top-selling product (and the world's best-selling drug), Humira, helped catapult its shares upward after it split from Abbott Laboratories. However, with cheap biosimilars being introduced in Europe in... | Sales of Humira declined slightly -- by 3.7% -- compared to the year-ago period, but that was despite the fact that revenue from AbbVie's top-selling product dropped by 33.5% internationally. AbbVie's (NYSE: ABBV) story in recent years is familiar to those who follow the pharmaceutical industry. These factors prompted ... | AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. The Allergan deal isn't looking so bad AbbVie's acquisition of Allergan (NYSE: AGN) in June was criticized for two major reasons. Better days ahead With the continued dominance of Humira in ... | AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company wi... | Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead. AbbVie's (NYSE: ABBV) story in recent years is familiar to those who follow the pharmaceutic... |
24,802 | 2019-12-03 00:00:00 UTC | Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors | ABBV | https://www.nasdaq.com/articles/merck-isnt-too-reliant-on-keytruda-yet-and-thats-good-news-for-investors-2019-12-03 | null | null | Merck (NYSE: MRK) has performed well on the stock market this year. Since early January, the company's shares are up by about 15%, which compares favorably to the return provided by the pharmaceutical industry -- as measured by the SPDR S&P Pharmaceuticals Index -- which is up 10% year to date. The main reason behind M... | For example, AbbVie's Humira was responsible for about 58% of the company's sales during the third quarter. The company's top-selling product continues to spearhead its top-line growth, but there's something investors should appreciate: Merck's revenue isn't too reliant on Keytruda. Investors should take notice Keytrud... | For example, AbbVie's Humira was responsible for about 58% of the company's sales during the third quarter. The company's sales were $12.4 billion, a 15% year-over-year increase, and Merck's non-GAAP earnings per share (EPS) improved by 27%. Most notably, Merck's vaccines lineup -- which includes cancer prevention vacc... | For example, AbbVie's Humira was responsible for about 58% of the company's sales during the third quarter. The company's top-selling product continues to spearhead its top-line growth, but there's something investors should appreciate: Merck's revenue isn't too reliant on Keytruda. Keytruda is currently being tested f... | For example, AbbVie's Humira was responsible for about 58% of the company's sales during the third quarter. Merck (NYSE: MRK) has performed well on the stock market this year. The main reason behind Merck's performance has been none other than its blockbuster cancer medicine Keytruda. |
24,803 | 2019-12-03 00:00:00 UTC | Insiders Buy the Holdings of MDIV ETF | ABBV | https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-mdiv-etf-2019-12-03 | null | null | A look at the weighted underlying holdings of the Multi-Asset Diversified Income Index Fund (MDIV) shows an impressive 10.8% of holdings on a weighted basis have experienced insider buying within the past six months.
Energy Transfer LP (Symbol: ET), which makes up 0.80% of the Multi-Asset Diversified Income Index Fund ... | The table below details the recent insider buying activity observed at ET: ET — last trade: $11.63 — Recent Insider Buys: And AbbVie Inc (Symbol: ABBV), the #45 largest holding among components of the Multi-Asset Diversified Income Index Fund (MDIV), shows 7 directors and officers as recently filing Form 4's indicating... | The table below details the recent insider buying activity observed at ET: ET — last trade: $11.63 — Recent Insider Buys: And AbbVie Inc (Symbol: ABBV), the #45 largest holding among components of the Multi-Asset Diversified Income Index Fund (MDIV), shows 7 directors and officers as recently filing Form 4's indicating... | The table below details the recent insider buying activity observed at ET: ET — last trade: $11.63 — Recent Insider Buys: And AbbVie Inc (Symbol: ABBV), the #45 largest holding among components of the Multi-Asset Diversified Income Index Fund (MDIV), shows 7 directors and officers as recently filing Form 4's indicating... | The table below details the recent insider buying activity observed at ET: ET — last trade: $11.63 — Recent Insider Buys: And AbbVie Inc (Symbol: ABBV), the #45 largest holding among components of the Multi-Asset Diversified Income Index Fund (MDIV), shows 7 directors and officers as recently filing Form 4's indicating... |
24,804 | 2019-12-03 00:00:00 UTC | 3 Words AbbVie Investors Really Didn't Want to Hear | ABBV | https://www.nasdaq.com/articles/3-words-abbvie-investors-really-didnt-want-to-hear-2019-12-03 | null | null | AbbVie (NYSE: ABBV) shareholders might not be exactly happy with the stock's performance in 2019. But they know it could be much worse. Only a few months ago, AbbVie was down more than 30% year to date. Since September, though, the big drugmaker has announced some positive pipeline news and delivered surprisingly posit... | But AbbVie received some unpleasant news last week in the form of an updated evidence report from the Institute for Clinical and Economic Review (ICER), an independent nonprofit group that evaluates the cost-effectiveness of healthcare treatments and tests. In the company's third-quarter conference call, for example, A... | This ICER report contained three words that AbbVie investors really didn't want to hear: "marginal clinical benefit." The organization's goal with this report was to analyze the cost-effectiveness of Eli Lilly's Olumiant, AbbVie's Rinvoq, and Pfizer's Xeljanz in treating rheumatoid arthritis (RA) compared to the curren... | The organization's goal with this report was to analyze the cost-effectiveness of Eli Lilly's Olumiant, AbbVie's Rinvoq, and Pfizer's Xeljanz in treating rheumatoid arthritis (RA) compared to the current gold standard for RA -- AbbVie's Humira. ICER's analysis found that AbbVie's new RA drug is only "modestly more effe... | This ICER report contained three words that AbbVie investors really didn't want to hear: "marginal clinical benefit." ICER's analysis found that AbbVie's new RA drug is only "modestly more effective" than the company's older RA drug. Nicer than ICER There are three words that should give AbbVie a level of comfort that ... |
24,805 | 2019-12-01 00:00:00 UTC | 3 Top Biotech Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-december-2019-12-01 | null | null | Will biotech stocks have a big year in 2020? I have no idea. But there are three stocks that I expect will deliver great returns over the long run and quite possibly will do so next year.
One's a dividend investor's dream. Another is a clinical-stage biotech that has plenty of big news on the way. And the third is argu... | AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie If you're looking for a stock with an absolutely mouthwatering dividend, look no further than AbbVie. And AbbVie has boosted its dividend payout by a whopping 195% since becoming a standalone company in 2013. | AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie If you're looking for a stock with an absolutely mouthwatering dividend, look no further than AbbVie. And AbbVie has boosted its dividend payout by a whopping 195% since becoming a standalone company in 2013. | See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie If you're looking for a stock with an absolutely mouthwatering dividend, look no further... | AbbVie If you're looking for a stock with an absolutely mouthwatering dividend, look no further than AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM), and Vertex Pharmaceuticals (N... |
24,806 | 2019-11-27 00:00:00 UTC | Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-dividend-growth-stock-thats-too-cheap-to-ignore-2019-11-27 | null | null | AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT) were born of the same parent but separated at birth. In 2013, Abbott Laboratories split into two companies, one primarily a medical device maker (which retained the parent's name) and the other a pharmaceutical company. That's where the similarities end, however. ... | Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decline in Humira's sales and AbbVie raised its 2019 full-year adjusted earnings per share (EPS) guidance. With $16 billion in annual revenue in mostly unrelated therapeutic ma... | Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decline in Humira's sales and AbbVie raised its 2019 full-year adjusted earnings per share (EPS) guidance. AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT) were born of ... | It's not surprising then that AbbVie's share price peaked in anticipation of the expiration of the European Union (EU) patent on Humira, which took place on Oct. 16, 2018. Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decl... | Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decline in Humira's sales and AbbVie raised its 2019 full-year adjusted earnings per share (EPS) guidance. In the third quarter, AbbVie continued its impressive streak of divid... |
24,807 | 2019-11-26 00:00:00 UTC | Is Myovant's New Prostate Cancer Drug a Game Changer? | ABBV | https://www.nasdaq.com/articles/is-myovants-new-prostate-cancer-drug-a-game-changer-2019-11-26 | null | null | A number of biotech stocks have made major moves over the past week. One of those was Myovant Sciences (NYSE: MYOV), a $1.1 billion biopharma company, which had its shares more than double on Nov. 19 following impressive clinical trial results in treating early, androgen-sensitive prostate cancer.
With hundreds of thou... | Instead, Myovant's relugolix would compete with leuprolide -- commonly known as Lupron -- which is owned by AbbVie (NYSE: ABBV), and a drug called Zoladex, which is owned by AstraZeneca. Uterine fibroid competition As for relugolix's potential as as a treatment for uterine fibroid-induced bleeding, Myovant's drug will ... | Uterine fibroid competition As for relugolix's potential as as a treatment for uterine fibroid-induced bleeding, Myovant's drug will soon be competing with AbbVie's own drug candidate, elagolix, which was recently submitted for FDA approval earlier this year following its own strong phase 3 trial results. Instead, Myov... | Uterine fibroid competition As for relugolix's potential as as a treatment for uterine fibroid-induced bleeding, Myovant's drug will soon be competing with AbbVie's own drug candidate, elagolix, which was recently submitted for FDA approval earlier this year following its own strong phase 3 trial results. Instead, Myov... | Uterine fibroid competition As for relugolix's potential as as a treatment for uterine fibroid-induced bleeding, Myovant's drug will soon be competing with AbbVie's own drug candidate, elagolix, which was recently submitted for FDA approval earlier this year following its own strong phase 3 trial results. Instead, Myov... |
24,808 | 2019-11-24 00:00:00 UTC | Better Buy: AbbVie vs. GlaxoSmithKline | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-glaxosmithkline-2019-11-24 | null | null | Big pharma stocks are a prized commodity among growth and income investors alike. The core reasons boil down to the fact that pharmaceuticals are an essential staple for millions of people, and the industry has been a hotbed of innovation over the past decade.
Nonetheless, pharmaceutical stocks do have a serious dark s... | AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) are two of the industry's most trusted names among value, growth, and income investors, thanks to their top-flight product portfolios and generous dividend programs. The case for AbbVie Illinois-based AbbVie began life in 2013. Post-split, Abbott became a medical prod... | Nonetheless, AbbVie was born with a hefty burden to bear -- namely, the eventual loss of exclusivity for top-selling immunology medicine Humira. Moreover, AbbVie's management has made a clear commitment to the company's dividend program, despite its junk bond-like yield of 5.46%. AbbVie (NYSE: ABBV) and GlaxoSmithKline... | AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) are two of the industry's most trusted names among value, growth, and income investors, thanks to their top-flight product portfolios and generous dividend programs. AbbVie, in kind, stands out as the more attractive income and growth play than Glaxo, although both st... | Moreover, AbbVie's management has made a clear commitment to the company's dividend program, despite its junk bond-like yield of 5.46%. AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) are two of the industry's most trusted names among value, growth, and income investors, thanks to their top-flight product portfolio... |
24,809 | 2019-11-24 00:00:00 UTC | 3 Dividend Stocks to Buy on Sale | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-on-sale-2019-11-24 | null | null | Major stock market indexes are hitting all-time highs. The current bull market is the longest one ever and is now in its 11th year. You might think it would be hard to find bargain stocks. And you probably think that it's even harder to find bargain dividend stocks.
While most dividend stocks are relatively pricey, th... | Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). AbbVie If you're looking for a dividend stock with a fantastic pedigree, you'll love AbbVie. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend ... | Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). AbbVie If you're looking for a dividend stock with a fantastic pedigree, you'll love AbbVie. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend ... | Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). Gilead Sciences Gilead Sciences admittedly doesn't have the impressive dividend track record of AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Kei... | But I don't think AbbVie's dividend will be in jeopardy at all because of the company's strategy to reduce its dependence on Humira. At the same time, competition increased, mainly from AbbVie. Verizon isn't quite as cheap as AbbVie and Gilead, but its valuation still appears to be quite attractive. |
24,810 | 2019-11-22 00:00:00 UTC | Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales | ABBV | https://www.nasdaq.com/articles/enanta-pharmaceuticals-q4-results-pulled-down-by-abbvies-sinking-hcv-sales-2019-11-22 | null | null | Enanta Pharmaceuticals' (NASDAQ: ENTA) got off to a great start in 2019 with its shares soaring more than 40%. It's been downhill since the first quarter, though. The pharma stock is now down more than 10% year to date.
Any hopes that Enanta's fiscal 2019 fourth-quarter results would help turn things around were dashed... | Behind the numbers Enanta made practically all of its revenue from royalties paid by AbbVie (NYSE: ABBV) on sales of hepatitis C virus (HCV) drug Mavyret. AbbVie stated in its third-quarter conference call that its global HCV revenue slipped from the prior-year period due to lower patient volumes and increased competit... | Behind the numbers Enanta made practically all of its revenue from royalties paid by AbbVie (NYSE: ABBV) on sales of hepatitis C virus (HCV) drug Mavyret. However, Enanta's total revenue fell because the company received a milestone payment of $15 million from AbbVie in the fourth quarter of 2018 and didn't have any mi... | However, Enanta's total revenue fell because the company received a milestone payment of $15 million from AbbVie in the fourth quarter of 2018 and didn't have any milestone payments in the recent quarter. Behind the numbers Enanta made practically all of its revenue from royalties paid by AbbVie (NYSE: ABBV) on sales o... | Behind the numbers Enanta made practically all of its revenue from royalties paid by AbbVie (NYSE: ABBV) on sales of hepatitis C virus (HCV) drug Mavyret. However, Enanta's total revenue fell because the company received a milestone payment of $15 million from AbbVie in the fourth quarter of 2018 and didn't have any mi... |
24,811 | 2019-11-21 00:00:00 UTC | AbbVie Shareholders Have a Lot to Look Forward To With Allergan | ABBV | https://www.nasdaq.com/articles/abbvie-shareholders-have-a-lot-to-look-forward-to-with-allergan-2019-11-21 | null | null | AbbVie's (NYSE: ABBV) third-quarterearnings callreminded investors about the transformative potential of the Allergan acquisition for the pharma giant. Management reiterated that they continue to expect the deal to close by the end of the first quarter of 2020. This is promising for investors, as the combined entity wi... | This is promising for investors, as the combined entity will allow AbbVie to gain a more diversified foothold in faster-growing therapeutic areas such as Botox and neuroscience while expanding its immunology portfolio with the addition of Allergan's Linzess and Viberzi. Not surprisingly, AbbVie will also have a market ... | AbbVie's (NYSE: ABBV) third-quarterearnings callreminded investors about the transformative potential of the Allergan acquisition for the pharma giant. This is promising for investors, as the combined entity will allow AbbVie to gain a more diversified foothold in faster-growing therapeutic areas such as Botox and neur... | This is promising for investors, as the combined entity will allow AbbVie to gain a more diversified foothold in faster-growing therapeutic areas such as Botox and neuroscience while expanding its immunology portfolio with the addition of Allergan's Linzess and Viberzi. Using full-year 2018 financials, adding AbbVie an... | AbbVie would be No. If that's not enough Year to date, AbbVie's stock price has been more or less flat, lagging the S&P 500. AbbVie's (NYSE: ABBV) third-quarterearnings callreminded investors about the transformative potential of the Allergan acquisition for the pharma giant. |
24,812 | 2019-11-21 00:00:00 UTC | January 2020 Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/january-2020-options-now-available-for-abbvie-abbv-2019-11-21 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2020 contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $92.50 strike highlighted in red: Considering the fact that the $92.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $80.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $92.50 strike price has a current bid of 11 cents. Below is a chart showing AB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2020 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $92.50 strike highlighted in red: Conside... |
24,813 | 2019-11-21 00:00:00 UTC | 1 Attractive Pharma Stock You Probably Haven't Heard Of | ABBV | https://www.nasdaq.com/articles/1-attractive-pharma-stock-you-probably-havent-heard-of-2019-11-21 | null | null | December will mark the one-year anniversary for the initial listing of American depositary shares on the New York Stock Exchange by Takeda Pharmaceutical (NYSE: TAK). Many U.S. investors are unfamiliar with the name, likely due to its relatively recent listing on a major U.S. exchange.
Founded in Japan over 230 years a... | For comparison, Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) sport P/E ratios of around 13, while those of AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) exceed 40. December will mark the one-year anniversary for the initial listing of American depositary shares on the New York Stock Exchange by Takeda Pharmaceuti... | For comparison, Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) sport P/E ratios of around 13, while those of AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) exceed 40. December will mark the one-year anniversary for the initial listing of American depositary shares on the New York Stock Exchange by Takeda Pharmaceuti... | For comparison, Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) sport P/E ratios of around 13, while those of AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) exceed 40. Added sales firepower with its Shire acquisition Takeda wrapped up its $62 billion acquisition of Shire in January 2019, touting that the combined com... | For comparison, Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) sport P/E ratios of around 13, while those of AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) exceed 40. Added sales firepower with its Shire acquisition Takeda wrapped up its $62 billion acquisition of Shire in January 2019, touting that the combined com... |
24,814 | 2019-11-18 00:00:00 UTC | Pfizer: FDA Approves ABRILADA As Biosimilar To Humira - Quick Facts | ABBV | https://www.nasdaq.com/articles/pfizer%3A-fda-approves-abrilada-as-biosimilar-to-humira-quick-facts-2019-11-18 | null | null | (RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.
ABRILADA is a tumor... | Pfizer said the company is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. (RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile id... | Pfizer said the company is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. (RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile id... | Pfizer said the company is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. (RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile id... | Pfizer said the company is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. (RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile id... |
24,815 | 2019-11-17 00:00:00 UTC | Better Buy: Eli Lilly vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy%3A-eli-lilly-vs.-abbvie-2019-11-17 | null | null | Neither Eli Lilly (NYSE: LLY) nor AbbVie (NYSE: ABBV) has provided much for investors to get excited about so far in 2019. Both big pharma stocks are down by single-digit percentages year to date. But Lilly and AbbVie each hold the potential to deliver more attractive returns down the stretch.
Which of these two stocks... | AbbVie will also pick up fast-growing antipsychotic drug Vraylar and birth control pill Lo Loestrin in addition to several other Allergan products with significant sales. Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, ... | Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta. Neither Eli Lilly (NYSE: LLY) nor AbbVie (NYSE: ABBV) has provided much for investors to get excited about so far in 2019. But Lilly and AbbVie eac... | Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta. Neither Eli Lilly (NYSE: LLY) nor AbbVie (NYSE: ABBV) has provided much for investors to get excited about so far in 2019. But Lilly and AbbVie eac... | AbbVie ranks as one of the most attractive dividend stocks on the market, with its dividend yielding nearly 5.5%. I expect that Eli Lilly will deliver stronger growth over the next several years than AbbVie will, though. Neither Eli Lilly (NYSE: LLY) nor AbbVie (NYSE: ABBV) has provided much for investors to get excite... |
24,816 | 2019-11-15 00:00:00 UTC | 5 Ways to Make Your Money Work for You | ABBV | https://www.nasdaq.com/articles/5-ways-to-make-your-money-work-for-you-2019-11-15 | null | null | "She works hard for the money
So hard for it, honey
She works hard for the money
So you better treat her right"
-- "She Works Hard for the Money," Donna Summer, from the 1983 album She Works Hard for the Money
Most of us are used to working hard for our money. We need our jobs in order to earn enough money to keep a r... | Selena Maranjian owns shares of AbbVie, Amazon, AT&T, Ford, IBM, Johnson & Johnson, and Verizon Communications. Fortunately, that dire situation also means that every such dollar of debt that you retire will give you a guaranteed return, by letting you no longer have to pay interest on it. Buy dividend-paying stocks Br... | Selena Maranjian owns shares of AbbVie, Amazon, AT&T, Ford, IBM, Johnson & Johnson, and Verizon Communications. Here's some evidence of that, via Wharton Business School professor Jeremy Siegel, who calculated the average returns for stocks, bonds, bills, gold, and the dollar between 1802 and 2012: Source: Stocks for t... | Selena Maranjian owns shares of AbbVie, Amazon, AT&T, Ford, IBM, Johnson & Johnson, and Verizon Communications. "She works hard for the money So hard for it, honey She works hard for the money So you better treat her right" -- "She Works Hard for the Money," Donna Summer, from the 1983 album She Works Hard for the Mone... | Selena Maranjian owns shares of AbbVie, Amazon, AT&T, Ford, IBM, Johnson & Johnson, and Verizon Communications. Carrying significant debt at high interest rates is a lot like investing -- in reverse. Invest in yourself Finally, a great way to put your money to work for you is to invest in yourself. |
24,817 | 2019-11-13 00:00:00 UTC | Why Does AbbVie Pay a Much Higher Dividend Than Its Peers? | ABBV | https://www.nasdaq.com/articles/why-does-abbvie-pay-a-much-higher-dividend-than-its-peers-2019-11-13 | null | null | AbbVie (NYSE: ABBV) is a major drug manufacturer best known for its product, Humira, which treats arthritis, Crohn's disease, and plaque psoriasis. At 5.02%, the company's dividend yield is by far the highest among its branded drug peers, with GlaxoSmithKline being the next highest at 4.19%, followed by Pfizer at 3.89%... | A major acquisition is the other big piece of this story In June 2019, AbbVie announced an agreement to acquire Allergan (NYSE: AGN), maker of well-known Botox, for $63 billion. AbbVie is paying a price-to-earnings multiple of nearly 50 to widen its pipeline, but it isn't acquiring any late-stage drugs that could appro... | A major acquisition is the other big piece of this story In June 2019, AbbVie announced an agreement to acquire Allergan (NYSE: AGN), maker of well-known Botox, for $63 billion. AbbVie (NYSE: ABBV) is a major drug manufacturer best known for its product, Humira, which treats arthritis, Crohn's disease, and plaque psori... | AbbVie will have to figure out how to replace Humira AbbVie holds patents in several countries for numerous applications for Humira, some of which have already begun to expire outside of the U.S. and will begin to expire domestically in 2023. AbbVie could be a very interesting story for investors who are seeking a high... | AbbVie is paying a price-to-earnings multiple of nearly 50 to widen its pipeline, but it isn't acquiring any late-stage drugs that could approach the Humira level of financial returns. AbbVie (NYSE: ABBV) is a major drug manufacturer best known for its product, Humira, which treats arthritis, Crohn's disease, and plaqu... |
24,818 | 2019-11-13 00:00:00 UTC | Should Investors Add Johnson & Johnson Stock to Their Shopping Lists? | ABBV | https://www.nasdaq.com/articles/should-investors-add-johnson-johnson-stock-to-their-shopping-lists-2019-11-13 | null | null | On Oct. 15, Johnson & Johnson (NYSE:), the healthcare giant, reported Q3 earnings and revenue that beat analysts’ average expectations. Yet, over the past 12 months, JNJ stock is down about 9%.
Source: Alexander Tolstykh / Shutterstock.com
Now many investors are wondering whether the company may end the year on a high ... | Professor Gabaldon further states that “Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive—a claim that clearly was untrue.” (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:) “also conducted aggressive advertising campaigns for their proprietary opioids. For example, in the summer, t... | Professor Gabaldon further states that “Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive—a claim that clearly was untrue.” (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:) “also conducted aggressive advertising campaigns for their proprietary opioids. On Oct. 15, Johnson & Johnson... | Professor Gabaldon further states that “Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive—a claim that clearly was untrue.” (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:) “also conducted aggressive advertising campaigns for their proprietary opioids. Analyzing JNJ’s Recent Earnin... | Professor Gabaldon further states that “Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive—a claim that clearly was untrue.” (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:) “also conducted aggressive advertising campaigns for their proprietary opioids. In the next few weeks, I expe... |
24,819 | 2019-11-13 00:00:00 UTC | Noteworthy ETF Outflows: IYH, MRK, PFE, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-iyh-mrk-pfe-abbv-2019-11-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $40.0 million dollar outflow -- that's a 1.9% decrease week over week (from 10,350,000 to 10,150,000). Among t... | Among the largest underlying components of IYH, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Pfizer Inc (Symbol: PFE) is off about 0.8%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of IYH, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Pfizer Inc (Symbol: PFE) is off about 0.8%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of IYH, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Pfizer Inc (Symbol: PFE) is off about 0.8%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, ... | Among the largest underlying components of IYH, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Pfizer Inc (Symbol: PFE) is off about 0.8%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perfor... |
24,820 | 2019-11-13 00:00:00 UTC | AbbVie Reaches Analyst Target Price | ABBV | https://www.nasdaq.com/articles/abbvie-reaches-analyst-target-price-2019-11-13 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $86.14, changing hands for $86.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a h... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $86.14, changing hands for $86.44/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $86.14, changing hands for $86.44/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | There are 7 different analyst targets contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. And so with ABBV crossing above that average target price of $86.14/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for ... | There are 7 different analyst targets contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $86.14, changing hands for $86.44/share. But the whole reason t... |
24,821 | 2019-11-13 00:00:00 UTC | Amarin's Stock Could Reach $50 Per Share Soon | ABBV | https://www.nasdaq.com/articles/amarins-stock-could-reach-%2450-per-share-soon-2019-11-13 | null | null | Yesterday, Amarin's (NASDAQ: AMRN) shares jumped by a whopping 20.9% during normal trading hours. The spark behind this eye-catching move northward was the release of the U.S. Food and Drug Administration's (FDA) briefing materials for the company's upcoming advisory-committee meeting set for this Thursday.
Come Thursd... | Keeping with this theme, Vascepa has the potential to generate annual sales larger than those of Pfizer's (NYSE: PFE) megablockbuster cholesterol medicine Lipitor, as well as AbbVie's anti-inflammatory behemoth Humira. Now, if a bidding war broke out -- a scenario that played out when AbbVie had to pay top dollar to ac... | Keeping with this theme, Vascepa has the potential to generate annual sales larger than those of Pfizer's (NYSE: PFE) megablockbuster cholesterol medicine Lipitor, as well as AbbVie's anti-inflammatory behemoth Humira. Now, if a bidding war broke out -- a scenario that played out when AbbVie had to pay top dollar to ac... | Keeping with this theme, Vascepa has the potential to generate annual sales larger than those of Pfizer's (NYSE: PFE) megablockbuster cholesterol medicine Lipitor, as well as AbbVie's anti-inflammatory behemoth Humira. Now, if a bidding war broke out -- a scenario that played out when AbbVie had to pay top dollar to ac... | Keeping with this theme, Vascepa has the potential to generate annual sales larger than those of Pfizer's (NYSE: PFE) megablockbuster cholesterol medicine Lipitor, as well as AbbVie's anti-inflammatory behemoth Humira. Now, if a bidding war broke out -- a scenario that played out when AbbVie had to pay top dollar to ac... |
24,822 | 2019-11-12 00:00:00 UTC | 7 Biotech Stocks to Buy With Plenty of Power in the Pipeline | ABBV | https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-2019-11-12 | null | null | As market conditions turn positive again and the major indices close at a new high, value investors should turn to the healthcare sector. Biotechnology stocks are far from their 52-week highs. And even though worries over pressured drug prices are dissipating, biotech stocks did not fully rebound.
Investors should look... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) stock recently began trading above $80 for the first time since May. Allergan’s product portfolio, especially the Botox lineup, broadens AbbVie’s pipeline of drugs. AbbVie advanced its pipeline with recent product Rinvoq. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) stock recently began trading above $80 for the first time since May. Allergan’s product portfolio, especially the Botox lineup, broadens AbbVie’s pipeline of drugs. AbbVie advanced its pipeline with recent product Rinvoq. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) stock recently began trading above $80 for the first time since May. Allergan’s product portfolio, especially the Botox lineup, broadens AbbVie’s pipeline of drugs. AbbVie advanced its pipeline with recent product Rinvoq. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) stock recently began trading above $80 for the first time since May. Allergan’s product portfolio, especially the Botox lineup, broadens AbbVie’s pipeline of drugs. AbbVie advanced its pipeline with recent product Rinvoq. |
24,823 | 2019-11-12 00:00:00 UTC | Why Shares of Reata Pharmaceuticals Rocketed More Than 150% in October | ABBV | https://www.nasdaq.com/articles/why-shares-of-reata-pharmaceuticals-rocketed-more-than-150-in-october-2019-11-12 | null | null | What happened
Shares of biopharma company Reata Pharmaceuticals (NASDAQ: RETA) climbed 156.7% in October, according to data from S&P Global Market Intelligence. Shares had been stagnant since January.
So what
Reata's big month came in three stages. First, shares increased by a modest 13% after the company announced it ... | The rights had formerly been licensed to Reata's partner AbbVie. First, shares increased by a modest 13% after the company announced it was buying back the rights to develop, produce, and market a series of next-generation Nrf2 activators, including bardoxolone and omaveloxolone. But the big jump -- 57% -- came on Oct.... | The rights had formerly been licensed to Reata's partner AbbVie. What happened Shares of biopharma company Reata Pharmaceuticals (NASDAQ: RETA) climbed 156.7% in October, according to data from S&P Global Market Intelligence. However, it's worth noting that Reata has now had two recent successes with this drug class: O... | The rights had formerly been licensed to Reata's partner AbbVie. But the big jump -- 57% -- came on Oct. 14, when Reata announced the positive top-line results of a midstage trial involving one of those drugs, omaveloxolone, and its potential to treat Friedreich's ataxia, a neurodegenerative disease caused by abnormall... | The rights had formerly been licensed to Reata's partner AbbVie. But the big jump -- 57% -- came on Oct. 14, when Reata announced the positive top-line results of a midstage trial involving one of those drugs, omaveloxolone, and its potential to treat Friedreich's ataxia, a neurodegenerative disease caused by abnormall... |
24,824 | 2019-11-11 00:00:00 UTC | 7 Great High-Yield Stocks With Payouts Over 5% | ABBV | https://www.nasdaq.com/articles/7-great-high-yield-stocks-with-payouts-over-5-2019-11-11 | null | null | In May, I recommended seven dividend stocks worth owning that were yielding 5% or more. In August, I gave the a bit of a refresh.
Now, with the S&P 500 on the verge of its since 2013, and only the fourth time in the past 20 years that the index has finished above 20%, I thought I’d pick an entirely new crop of high-yi... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, you’re looking like a regular genius right about now. Up 30% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.8%. How did AbbVie drop so far after starting 2019 around $90? | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, you’re looking like a regular genius right about now. Up 30% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.8%. How did AbbVie drop so far after starting 2019 around $90? | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, you’re looking like a regular genius right about now. Up 30% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.8%. How did AbbVie drop so far after starting 2019 around $90? | The big reason AbbVie management bit the bullet on Allergan was to give itself time to find for Humira. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, you’re looking like a regular genius right about now. Up 30% from its 52-week low of $62.66, ABBV stock is stil... |
24,825 | 2019-11-11 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2019-11-11 | null | null | As healthcare costs outpace the rise in inflation, the U.S. will soon spend about 20% of the gross domestic product on healthcare. Smart investors are eyeing key healthcare stocks set to outperform in the next year.
Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks wo... | Now is the time to buy Veeva Systems, AbbVie, and Novartis are three health stocks that can generate lucrative returns for investors in the long-run. Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks worth considering for your stock portfolio. AbbVie Abbvie was spun-o... | Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks worth considering for your stock portfolio. AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. A... | Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks worth considering for your stock portfolio. AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. A... | Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks worth considering for your stock portfolio. AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. A... |
24,826 | 2019-11-10 00:00:00 UTC | This Terrific High-Yield Dividend Stock Just Got Even Better | ABBV | https://www.nasdaq.com/articles/this-terrific-high-yield-dividend-stock-just-got-even-better-2019-11-10 | null | null | What's better than a stock that pays great dividends? A stock that pays great dividends and keeps hiking those dividends.
That's exactly what AbbVie (NYSE: ABBV) has done since being spun off from Abbott Labs in 2013, raising its dividend every year. If you count the period when AbbVie was part of Abbott, the company e... | If you count the period when AbbVie was part of Abbott, the company entered 2019 with a 46-year streak of consecutive annual dividend hikes. With sales for Humira in jeopardy and serious questions about the Allergan buyout, can AbbVie keep its dividend program going as strong as it has in the past? AbbVie expects that ... | If you count the period when AbbVie was part of Abbott, the company entered 2019 with a 46-year streak of consecutive annual dividend hikes. This latest dividend hike also makes AbbVie's sky-high dividend yield even more attractive. That's exactly what AbbVie (NYSE: ABBV) has done since being spun off from Abbott Labs ... | A Dividend King in the making AbbVie CEO Rick Gonzalez stated in the company's Q3 conference call that AbbVie remains "committed to a strong and growing dividend." Including its time as part of Abbott, AbbVie already belongs to the group of stocks known as Dividend Aristocrats -- companies that have increased their div... | Can AbbVie keep it up? I think that AbbVie is a Dividend King in the making and one of the best dividend stocks on the market right now. That's exactly what AbbVie (NYSE: ABBV) has done since being spun off from Abbott Labs in 2013, raising its dividend every year. |
24,827 | 2019-11-09 00:00:00 UTC | 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now | ABBV | https://www.nasdaq.com/articles/2-biotech-stocks-fighting-alzheimers-disease-to-own-now-2019-11-09 | null | null | The Alzheimer's community got a boost at the end of October when Biogen (NASDAQ: BIIB) announced it would file for approval from the U.S. Food and Drug Administration for aducanumab, its Alzheimer's disease drug. This caught patients and investors off guard since Biogen scrapped the program back in March due to lack of... | AbbVie (NYSE: ABBV) paid $205 million in cash and made a $20 million equity investment in 2017 to collaborate with Alector to generate new Alzheimer's drugs. If AbbVie opts to take on the future development, Alector could receive up to $985.6 million in additional milestone payments. That's why it is important to have ... | AbbVie (NYSE: ABBV) paid $205 million in cash and made a $20 million equity investment in 2017 to collaborate with Alector to generate new Alzheimer's drugs. If AbbVie opts to take on the future development, Alector could receive up to $985.6 million in additional milestone payments. That's why it is important to have ... | AbbVie (NYSE: ABBV) paid $205 million in cash and made a $20 million equity investment in 2017 to collaborate with Alector to generate new Alzheimer's drugs. If AbbVie opts to take on the future development, Alector could receive up to $985.6 million in additional milestone payments. That's why it is important to have ... | AbbVie (NYSE: ABBV) paid $205 million in cash and made a $20 million equity investment in 2017 to collaborate with Alector to generate new Alzheimer's drugs. If AbbVie opts to take on the future development, Alector could receive up to $985.6 million in additional milestone payments. That's why it is important to have ... |
24,828 | 2019-11-08 00:00:00 UTC | Friday Sector Leaders: Healthcare, Technology & Communications | ABBV | https://www.nasdaq.com/articles/friday-sector-leaders%3A-healthcare-technology-communications-2019-11-08 | null | null | Looking at the sectors faring best as of midday Friday, shares of Healthcare companies are outperforming other sectors, up 0.6%. Within the sector, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 4.5% and 3.9%, respectively. Among heal... | Combined, REGN and ABBV make up approximately 3.9% of the underlying holdings of XLV. Within the sector, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 4.5% and 3.9%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is down 8... | Within the sector, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 4.5% and 3.9%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is down 8.66% year-to-date, and AbbVie Inc, is down 2.90% year-to-date. Combined, REGN and ABBV... | Within the sector, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 4.5% and 3.9%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is down 8.66% year-to-date, and AbbVie Inc, is down 2.90% year-to-date. Combined, REGN and ABBV... | Within the sector, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 4.5% and 3.9%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is down 8.66% year-to-date, and AbbVie Inc, is down 2.90% year-to-date. Combined, REGN and ABBV... |
24,829 | 2019-11-08 00:00:00 UTC | 10 Medical Marijuana Stocks to Cure Your Portfolio | ABBV | https://www.nasdaq.com/articles/10-medical-marijuana-stocks-to-cure-your-portfolio-2019-11-08 | null | null | [Editor’s note: “10 Medical Marijuana Stocks to Cure Your Portfolio” was previously published in October 2019. It has since been updated to include the most relevant information available.]
Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, toward ... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... |
24,830 | 2019-11-06 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2019-11-06 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
24,831 | 2019-11-05 00:00:00 UTC | Noteworthy ETF Outflows: DGRO, VZ, PFE, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-dgro-vz-pfe-abbv-2019-11-05 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $86.8 million dollar outflow -- that's a 0.9% decrease week over week (from 228,950,000 to 226,800,000).... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 0.4%, Pfizer Inc (Symbol: PFE) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one y... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 0.4%, Pfizer Inc (Symbol: PFE) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one y... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 0.4%, Pfizer Inc (Symbol: PFE) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 0.4%, Pfizer Inc (Symbol: PFE) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one y... |
24,832 | 2019-11-02 00:00:00 UTC | 3 Most Important Takeaways From AbbVie's Q3 Results | ABBV | https://www.nasdaq.com/articles/3-most-important-takeaways-from-abbvies-q3-results-2019-11-02 | null | null | AbbVie (NYSE: ABBV) has kind of been the Rodney Dangerfield of big pharma stocks. To paraphrase the late comedian's famous punch line: It don't get no respect.
But AbbVie just might be getting some grudging respect from investors after the company announced its third-quarter results on Friday. While those results weren... | In addition to posting upside surprises on its top and bottom lines, AbbVie upped its full-year 2019 guidance. AbbVie (NYSE: ABBV) has kind of been the Rodney Dangerfield of big pharma stocks. But AbbVie just might be getting some grudging respect from investors after the company announced its third-quarter results on ... | But AbbVie just might be getting some grudging respect from investors after the company announced its third-quarter results on Friday. But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-y... | But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. The higher sales for the drug in the U.S. market translated to more than $370 million added to AbbVie's top line. AbbVie an... | But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. The higher sales for the drug in the U.S. market translated to more than $370 million added to AbbVie's top line. AbbVie (N... |
24,833 | 2019-11-01 00:00:00 UTC | What Happened in the Stock Market Today | ABBV | https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-11-01 | null | null | Major benchmarks rose Friday after a strong jobs report showed that the U.S. economy added more jobs in October than observers expected. The S&P 500 (SNPINDEX: ^GSPC) set a new record and the Dow Jones Industrial Average (DJINDICES: ^DJI) also saw strong gains. Energy and industrial stocks moved higher, while the rate-... | Looking forward, AbbVie raised the low end of adjusted EPS guidance for the full year by $0.08 to $8.90 to $8.92, representing year-over-year growth of 12.6%. As for individual stocks, Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) subsidiary Google plans to acquire Fitbit (NYSE: FIT), and AbbVie (NYSE: ABBV) reported third-q... | As for individual stocks, Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) subsidiary Google plans to acquire Fitbit (NYSE: FIT), and AbbVie (NYSE: ABBV) reported third-quarter results that beat expectations on the top and bottom lines. AbbVie beats expectations, raises dividend Pharmaceutical giant AbbVie beat third-quarter ex... | As for individual stocks, Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) subsidiary Google plans to acquire Fitbit (NYSE: FIT), and AbbVie (NYSE: ABBV) reported third-quarter results that beat expectations on the top and bottom lines. AbbVie beats expectations, raises dividend Pharmaceutical giant AbbVie beat third-quarter ex... | AbbVie beats expectations, raises dividend Pharmaceutical giant AbbVie beat third-quarter expectations, raised its outlook, and increased its dividend, sending shares up 2.8%. As for individual stocks, Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) subsidiary Google plans to acquire Fitbit (NYSE: FIT), and AbbVie (NYSE: ABBV)... |
24,834 | 2019-11-01 00:00:00 UTC | 6 Top Stock Trades for Monday: BABA, PINS, CVX | ABBV | https://www.nasdaq.com/articles/6-top-stock-trades-for-monday%3A-baba-pins-cvx-2019-11-01 | null | null | A better-than-expected jobs report thrust equities to new all-time highs once again, with the S&P 500 notching its fourth new high in five days. Let’s take a look at a few top stock trades as the markets continue to roll higher.
Top Stock Trades for Tomorrow No. 1: Alibaba (BABA)
Alibaba (NYSE:) is barely in positive t... | 3: AbbVie (ABBV) AbbVie (NYSE:) stock has been on fire, and Friday’s post-earnings rally is only adding fuel to that fire. Let’s see if the 100-week moving average gives ABBV any issues, up at $83.50. If the 100-week moving average is resistance, see if ABBV finds support either at the 50-week or 200-week moving averag... | 3: AbbVie (ABBV) AbbVie (NYSE:) stock has been on fire, and Friday’s post-earnings rally is only adding fuel to that fire. Let’s see if the 100-week moving average gives ABBV any issues, up at $83.50. If the 100-week moving average is resistance, see if ABBV finds support either at the 50-week or 200-week moving averag... | If the 100-week moving average is resistance, see if ABBV finds support either at the 50-week or 200-week moving average. 3: AbbVie (ABBV) AbbVie (NYSE:) stock has been on fire, and Friday’s post-earnings rally is only adding fuel to that fire. Let’s see if the 100-week moving average gives ABBV any issues, up at $83.5... | 3: AbbVie (ABBV) AbbVie (NYSE:) stock has been on fire, and Friday’s post-earnings rally is only adding fuel to that fire. Let’s see if the 100-week moving average gives ABBV any issues, up at $83.50. If the 100-week moving average is resistance, see if ABBV finds support either at the 50-week or 200-week moving averag... |
24,835 | 2019-11-01 00:00:00 UTC | Daily Dividend Report: ABBV, WLKP, AIG, EXC, COF | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-abbv-wlkp-aig-exc-cof-2019-11-01 | null | null | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent,... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent,... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent,... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent,... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent,... |
24,836 | 2019-11-01 00:00:00 UTC | 2019's Biggest Mergers and Acquisitions (So Far) | ABBV | https://www.nasdaq.com/articles/2019s-biggest-mergers-and-acquisitions-so-far-2019-11-01 | null | null | M
ergers and acquisitions are one of the ways for a company to grow and expand its business. M&As enable companies to extend their global footprint, diversify across geographies, gain access to better technological know-how and other resources, benefit from consolidating strategic imperatives, add complementary product... | The acquisition is in sync with Saudi Aramco’s long-term strategy to “drive growth through an enhanced line with Downstream portfolio by increasing global participated refining capacity from 4.9 million to 8-10 million barrels per day by 2030.” AbbVie’s bid for Allergan In June 2019, AbbVie Inc. (ABBV) entered into a d... | The acquisition is in sync with Saudi Aramco’s long-term strategy to “drive growth through an enhanced line with Downstream portfolio by increasing global participated refining capacity from 4.9 million to 8-10 million barrels per day by 2030.” AbbVie’s bid for Allergan In June 2019, AbbVie Inc. (ABBV) entered into a d... | The acquisition is in sync with Saudi Aramco’s long-term strategy to “drive growth through an enhanced line with Downstream portfolio by increasing global participated refining capacity from 4.9 million to 8-10 million barrels per day by 2030.” AbbVie’s bid for Allergan In June 2019, AbbVie Inc. (ABBV) entered into a d... | The acquisition is in sync with Saudi Aramco’s long-term strategy to “drive growth through an enhanced line with Downstream portfolio by increasing global participated refining capacity from 4.9 million to 8-10 million barrels per day by 2030.” AbbVie’s bid for Allergan In June 2019, AbbVie Inc. (ABBV) entered into a d... |
24,837 | 2019-11-01 00:00:00 UTC | Health Care Sector Update for 11/01/2019: ABBV, EIDX, MD, JNJ, PFE, ABT, MRK, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-11-01-2019%3A-abbv-eidx-md-jnj-pfe-abt-mrk-amgn-2019-11-01 | null | null | Top Health Care Stocks:
JNJ: +0.33%
PFE: +0.55%
ABT: -0.37%
MRK: +0.51%
AMGN: +0.70%
Most health care majors were gaining pre-bell Friday.
In other sector news:
(+) AbbVie (ABBV) was slightly higher after it reported Q3 adjusted diluted earnings per share of $2.33, up from $2.14 during the year-ago quarter, and beating... | In other sector news: (+) AbbVie (ABBV) was slightly higher after it reported Q3 adjusted diluted earnings per share of $2.33, up from $2.14 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.30. Most health care majors were gaining pre-bell Friday. (=) Mednax (MD) was unchanged after it r... | In other sector news: (+) AbbVie (ABBV) was slightly higher after it reported Q3 adjusted diluted earnings per share of $2.33, up from $2.14 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.30. Top Health Care Stocks: Most health care majors were gaining pre-bell Friday. | In other sector news: (+) AbbVie (ABBV) was slightly higher after it reported Q3 adjusted diluted earnings per share of $2.33, up from $2.14 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.30. Most health care majors were gaining pre-bell Friday. (=) Eidos Therapeutics (EIDX) was flat a... | In other sector news: (+) AbbVie (ABBV) was slightly higher after it reported Q3 adjusted diluted earnings per share of $2.33, up from $2.14 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.30. Top Health Care Stocks: The Street was forecasting a loss of $0.27 per share. |
24,838 | 2019-11-01 00:00:00 UTC | AbbVie Boosts FY19 Adj. EPS Outlook; Boosts Dividend 10.2% - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-boosts-fy19-adj.-eps-outlook-boosts-dividend-10.2-quick-facts-2019-11-01 | null | null | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2019.
For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.90 to $8.92 per share, up from the prior guidance range of $8.... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2019. Further, AbbVie announced that its board of directors declared a 10.3 percent higher quarterly cash dividend of $1.18 per share beginn... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.90 to $8.92 per share, up from the prior guidance range of $8.... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.90 to $8.92 per share, up from the prior guidance range of $8.... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2019. Further, AbbVie announced that its board of directors declared a 10.3 percent higher quarterly cash dividend of $1.18 per share beginn... |
24,839 | 2019-11-01 00:00:00 UTC | Novartis: Cosentyx Shows Positive Results Vs Humira In Psoriatic Arthritis Trial | ABBV | https://www.nasdaq.com/articles/novartis%3A-cosentyx-shows-positive-results-vs-humira-in-psoriatic-arthritis-trial-2019-11 | null | null | (RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Cosentyx shows encouraging results versus Humira from first-of-its-kind head-to-head trial in psoriatic arthritis.
In a statement, the company announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab)... | In a statement, the company announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab), of AbbVie Inc., in patients with active psoriatic arthritis or PsA. (RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Cosentyx shows encouraging results versus Hum... | In a statement, the company announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab), of AbbVie Inc., in patients with active psoriatic arthritis or PsA. (RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Cosentyx shows encouraging results versus Hum... | In a statement, the company announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab), of AbbVie Inc., in patients with active psoriatic arthritis or PsA. (RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Cosentyx shows encouraging results versus Hum... | In a statement, the company announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab), of AbbVie Inc., in patients with active psoriatic arthritis or PsA. (RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Cosentyx shows encouraging results versus Hum... |
24,840 | 2019-10-31 00:00:00 UTC | Noteworthy Thursday Option Activity: ABBV, BLD, BCOV | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-abbv-bld-bcov-2019-10-31 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 34,952 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that e... | Especially high volume was seen for the $81 strike call option expiring November 01, 2019, with 3,090 contracts trading so far today, representing approximately 309,000 underlying shares of ABBV. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 34,952 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that e... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 34,952 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that e... | Below is a chart showing ABBV's trailing twelve month trading history, with the $81 strike highlighted in orange: TopBuild Corp (Symbol: BLD) saw options trading volume of 1,250 contracts, representing approximately 125,000 underlying shares or approximately 52% of BLD's average daily trading volume over the past month... |
24,841 | 2019-10-31 00:00:00 UTC | 3 Breakout Stocks to Buy for the Rest of 2019 | ABBV | https://www.nasdaq.com/articles/3-breakout-stocks-to-buy-for-the-rest-of-2019-2019-10-31 | null | null | The current sentiment on Wall Street is completely different than this time last year. Back then, the Federal Reserve had mistakenly spooked investors into thinking they would continue their rate hike cycle in spite of softening economies. Things are much different in 2019. Case in point: Yesterday the Fed cut rates fo... | Today we examine CVS (NYSE:), AbbVie (NYSE:) and Square (NYSE:). AbbVie (ABBV) Similarly to CVS, ABBV stock is also facing the opportunity of a bullish pattern breakout. So far this year ABBV stock is down 14% when the S&P 500 just set a new all-time high. | Today we examine CVS (NYSE:), AbbVie (NYSE:) and Square (NYSE:). AbbVie (ABBV) Similarly to CVS, ABBV stock is also facing the opportunity of a bullish pattern breakout. So far this year ABBV stock is down 14% when the S&P 500 just set a new all-time high. | Today we examine CVS (NYSE:), AbbVie (NYSE:) and Square (NYSE:). AbbVie (ABBV) Similarly to CVS, ABBV stock is also facing the opportunity of a bullish pattern breakout. So far this year ABBV stock is down 14% when the S&P 500 just set a new all-time high. | So far this year ABBV stock is down 14% when the S&P 500 just set a new all-time high. Today we examine CVS (NYSE:), AbbVie (NYSE:) and Square (NYSE:). AbbVie (ABBV) Similarly to CVS, ABBV stock is also facing the opportunity of a bullish pattern breakout. |
24,842 | 2019-10-29 00:00:00 UTC | Can New Drugs Help Gilead Sciences Rebound? | ABBV | https://www.nasdaq.com/articles/can-new-drugs-help-gilead-sciences-rebound-2019-10-29 | null | null | Gilead Sciences (NASDAQ: GILD) put up a rather lackluster third-quarter report last week. Revenue was flat year over year, dragged down by a 20% decline in sales of its hepatitis C franchise, as well as lower sales of angina drug Ranexa and pulmonary arterial hypertension drug Letairis as both drugs face generic compet... | The drug faces competition from already-approved JAK inhibitors, Eli Lilly's (NYSE: LLY) Olumiant, Pfizer's (NYSE: PFE) Xeljanz, and AbbVie's (NYSE: ABBV) Rinvoq, but Mercier thinks filgotinib could have an edge: One of the things that I would say is the importance of our data and I think that if you look at the result... | The drug faces competition from already-approved JAK inhibitors, Eli Lilly's (NYSE: LLY) Olumiant, Pfizer's (NYSE: PFE) Xeljanz, and AbbVie's (NYSE: ABBV) Rinvoq, but Mercier thinks filgotinib could have an edge: One of the things that I would say is the importance of our data and I think that if you look at the result... | The drug faces competition from already-approved JAK inhibitors, Eli Lilly's (NYSE: LLY) Olumiant, Pfizer's (NYSE: PFE) Xeljanz, and AbbVie's (NYSE: ABBV) Rinvoq, but Mercier thinks filgotinib could have an edge: One of the things that I would say is the importance of our data and I think that if you look at the result... | The drug faces competition from already-approved JAK inhibitors, Eli Lilly's (NYSE: LLY) Olumiant, Pfizer's (NYSE: PFE) Xeljanz, and AbbVie's (NYSE: ABBV) Rinvoq, but Mercier thinks filgotinib could have an edge: One of the things that I would say is the importance of our data and I think that if you look at the result... |
24,843 | 2019-10-26 00:00:00 UTC | 5 Top Healthcare ETFs | ABBV | https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26 | null | null | Healthcare is huge. In 2017, healthcare spending in the U.S. totaled $3.5 trillion -- nearly 18% of the country's gross domestic product (GDP), which is the total market value of all products and services produced. Worldwide healthcare spending topped $7.7 billion. By 2022, global healthcare spending will reach at leas... | The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Like the Health Care Select SPDR Fund, the ETF's largest holdings... | The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Like the Health Care Select SPDR Fund, the ETF's largest holdings... | The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Like the Health Care Select SPDR Fund, the ETF's largest holdings... | The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Like the Health Care Select SPDR Fund, the ETF's largest holdings... |
24,844 | 2019-10-25 00:00:00 UTC | Don’t Sleep on These 2 Pharmaceutical Stocks | ABBV | https://www.nasdaq.com/articles/dont-sleep-on-these-2-pharmaceutical-stocks-2019-10-25 | null | null | It hasn't been a great year for pharma companies. The industry, as measured by the SPDR S&P Pharmaceuticals Index, is up less than 1.5% since the beginning of the year, a period during which the S&P has gained about 18%. And some big players have had it far worse. Case in point: AbbVie (NYSE: ABBV) stock is down by 13%... | AbbVie recently acquired Allergan for about $63 billion, a blockbuster deal that strengthened its portfolio of drugs and gave it more avenues to find new potentially high-revenue treatments. Case in point: AbbVie (NYSE: ABBV) stock is down by 13% year to date, while Eli Lilly (NYSE: LLY) shares are down by 7%. More tha... | Case in point: AbbVie (NYSE: ABBV) stock is down by 13% year to date, while Eli Lilly (NYSE: LLY) shares are down by 7%. More than Humira AbbVie has become practically synonymous with Humira, and with good reason. Last year, for example, sales of Humira came in at $13.6 billion -- 63.5% of AbbVie's adjusted net revenue... | Case in point: AbbVie (NYSE: ABBV) stock is down by 13% year to date, while Eli Lilly (NYSE: LLY) shares are down by 7%. Last year, for example, sales of Humira came in at $13.6 billion -- 63.5% of AbbVie's adjusted net revenues. More than Humira AbbVie has become practically synonymous with Humira, and with good reaso... | Last year, for example, sales of Humira came in at $13.6 billion -- 63.5% of AbbVie's adjusted net revenues. Case in point: AbbVie (NYSE: ABBV) stock is down by 13% year to date, while Eli Lilly (NYSE: LLY) shares are down by 7%. More than Humira AbbVie has become practically synonymous with Humira, and with good reaso... |
24,845 | 2019-10-25 00:00:00 UTC | Vanguard Health Care ETF -- Insider Buying Index Registering 14.7% | ABBV | https://www.nasdaq.com/articles/vanguard-health-care-etf-insider-buying-index-registering-14.7-2019-10-25 | null | null | A look at the weighted underlying holdings of the Vanguard Health Care ETF (Symbol: VHT) shows an impressive 14.7% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 2.79% of the Vanguard Health Care ETF (Symbol: VHT), has seen 7 directo... | AbbVie Inc (Symbol: ABBV), which makes up 2.79% of the Vanguard Health Care ETF (Symbol: VHT), has seen 7 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $76.80 — Recent In... | AbbVie Inc (Symbol: ABBV), which makes up 2.79% of the Vanguard Health Care ETF (Symbol: VHT), has seen 7 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $76.80 — Recent In... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $76.80 — Recent Insider Buys: And Heron Therapeutics Inc (Symbol: HRTX), the #158 largest holding among components of the Vanguard Health Care ETF (Symbol: VHT), shows 4 directors and officers as recently filing Form 4's ind... | AbbVie Inc (Symbol: ABBV), which makes up 2.79% of the Vanguard Health Care ETF (Symbol: VHT), has seen 7 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $288,649,190 worth of ABBV, making it the #9 largest holding. The table below details the... |
24,846 | 2019-10-24 00:00:00 UTC | NOBL, BF.B, ABBV, AOS: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/nobl-bf.b-abbv-aos%3A-etf-inflow-alert-2019-10-24 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares ProShares S&P 500 Dividend Aristocrats ETF (Symbol: NOBL) where we have detected an approximate $108.1 million dollar inflow -- that's a 1.9% increase week over week in outstanding... | Among the largest underlying components of NOBL, in trading today Brown-Forman Corp (Symbol: BF.B) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 1.3%, and Smith (A O) Corp (Symbol: AOS) is lower by about 0.6%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one year... | Among the largest underlying components of NOBL, in trading today Brown-Forman Corp (Symbol: BF.B) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 1.3%, and Smith (A O) Corp (Symbol: AOS) is lower by about 0.6%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one year... | Among the largest underlying components of NOBL, in trading today Brown-Forman Corp (Symbol: BF.B) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 1.3%, and Smith (A O) Corp (Symbol: AOS) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of NOBL, in trading today Brown-Forman Corp (Symbol: BF.B) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 1.3%, and Smith (A O) Corp (Symbol: AOS) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
24,847 | 2019-10-22 00:00:00 UTC | Goldman Sachs: 3 High-Yield Dividend Stocks With Growth on the Horizon | ABBV | https://www.nasdaq.com/articles/goldman-sachs%3A-3-high-yield-dividend-stocks-with-growth-on-the-horizon-2019-10-22 | null | null | Investors have voted with their wallets, and the verdict is in: they want income and growth. That shouldn’t be surprising, as income and growth are the keys to profitable investing, but market conditions have been volatile in the last 12 months. With share appreciation unreliable, investors have turned to dividends.
Di... | (See Citizens Financial stock analysis on TipRanks) AbbVie (ABBV) This large-cap pharmaceutical giant has been pursuing a successful two-path growth strategy, making acquisitions for expansion and reaping profits from new medications (SKYRIZI) and established drugs (Humira). The AbbVie faced risk on the Humira front, h... | (See Citizens Financial stock analysis on TipRanks) AbbVie (ABBV) This large-cap pharmaceutical giant has been pursuing a successful two-path growth strategy, making acquisitions for expansion and reaping profits from new medications (SKYRIZI) and established drugs (Humira). The AbbVie faced risk on the Humira front, h... | (See Citizens Financial stock analysis on TipRanks) AbbVie (ABBV) This large-cap pharmaceutical giant has been pursuing a successful two-path growth strategy, making acquisitions for expansion and reaping profits from new medications (SKYRIZI) and established drugs (Humira). The AbbVie faced risk on the Humira front, h... | (See Citizens Financial stock analysis on TipRanks) AbbVie (ABBV) This large-cap pharmaceutical giant has been pursuing a successful two-path growth strategy, making acquisitions for expansion and reaping profits from new medications (SKYRIZI) and established drugs (Humira). The AbbVie faced risk on the Humira front, h... |
24,848 | 2019-10-22 00:00:00 UTC | Which High-Yield Dividend Aristocrat Is the Best Buy? | ABBV | https://www.nasdaq.com/articles/which-high-yield-dividend-aristocrat-is-the-best-buy-2019-10-22 | null | null | Dividend Aristocrats are a select group of S&P 500 companies that have raised their dividends for a minimum of 25 consecutive years. What's particularly noteworthy about these income-generating equities is that Dividend Aristocrats, as a whole, have beaten the broader markets -- as well as the vast majority of sector-s... | AbbVie is set to merge with Botox maker Allergan, which is expected to provide a significant boost to its earnings per share over the next three consecutive years. The pharmaceutical titan AbbVie (NYSE: ABBV), the telecom giant AT&T (NYSE: T), and the oil and gas behemoth ExxonMobil (NYSE: XOM) all offer forward annual... | The pharmaceutical titan AbbVie (NYSE: ABBV), the telecom giant AT&T (NYSE: T), and the oil and gas behemoth ExxonMobil (NYSE: XOM) all offer forward annual dividend yields greater than 5%. In terms of forward annual dividend yield, AbbVie comes in at 5.6%, which tops the yields of both AT&T (5.3%) and ExxonMobil (5.15... | In terms of forward annual dividend yield, AbbVie comes in at 5.6%, which tops the yields of both AT&T (5.3%) and ExxonMobil (5.15%). The pharmaceutical titan AbbVie (NYSE: ABBV), the telecom giant AT&T (NYSE: T), and the oil and gas behemoth ExxonMobil (NYSE: XOM) all offer forward annual dividend yields greater than ... | In terms of forward annual dividend yield, AbbVie comes in at 5.6%, which tops the yields of both AT&T (5.3%) and ExxonMobil (5.15%). AbbVie, then, offers the highest yield among all Dividend Aristocrats. The pharmaceutical titan AbbVie (NYSE: ABBV), the telecom giant AT&T (NYSE: T), and the oil and gas behemoth ExxonM... |
24,849 | 2019-10-22 00:00:00 UTC | Is TG Therapeutics a Buy? | ABBV | https://www.nasdaq.com/articles/is-tg-therapeutics-a-buy-2019-10-22 | null | null | One of the current top-performing autoimmune disease biotech firms in the market, at least in terms of performance, is TG Therapeutics (NASDAQ: TGTX). Throughout the first half of 2019, TG Therapeutics was one of the most promising biotech stocks in the sector, with shares rising by as much as 224% between February and... | Pharmaceutical giants such as Gilead, Bristol-Myers, and AbbVie (NYSE: ABBV) are all competing in the blood cancer and hematology fields with drugs candidates that have seen comparable results to TG's umbra and ubli. AbbVie in particular has been emphasizing its leukemia drug Venclexta, which has already received recen... | Pharmaceutical giants such as Gilead, Bristol-Myers, and AbbVie (NYSE: ABBV) are all competing in the blood cancer and hematology fields with drugs candidates that have seen comparable results to TG's umbra and ubli. AbbVie in particular has been emphasizing its leukemia drug Venclexta, which has already received recen... | Pharmaceutical giants such as Gilead, Bristol-Myers, and AbbVie (NYSE: ABBV) are all competing in the blood cancer and hematology fields with drugs candidates that have seen comparable results to TG's umbra and ubli. AbbVie in particular has been emphasizing its leukemia drug Venclexta, which has already received recen... | Pharmaceutical giants such as Gilead, Bristol-Myers, and AbbVie (NYSE: ABBV) are all competing in the blood cancer and hematology fields with drugs candidates that have seen comparable results to TG's umbra and ubli. AbbVie in particular has been emphasizing its leukemia drug Venclexta, which has already received recen... |
24,850 | 2019-10-18 00:00:00 UTC | 3 Companies to Watch At Kidney Week 2019 | ABBV | https://www.nasdaq.com/articles/3-companies-to-watch-at-kidney-week-2019-2019-10-18 | null | null | While earnings season is under way, investors in biotech stocks must also stay abreast of the latest data emerging from major medical meetings. At these events, biotech and pharmaceutical companies vie for top billing to showcase the latest results on clinical trials and new drug candidates.
The American Society of Nep... | The company reacquired global rights to some of its drug candidates from AbbVie (NYSE: ABBV) and presented positive clinical data in a study involving omaveloxolone to treat Friedreich's ataxia. Last month, Ra Pharmaceuticals (NASDAQ: RARX), another biotech company developing drugs targeting the complement pathway, ann... | The company reacquired global rights to some of its drug candidates from AbbVie (NYSE: ABBV) and presented positive clinical data in a study involving omaveloxolone to treat Friedreich's ataxia. The American Society of Nephrology Annual Meeting, also known as Kidney Week, will take place from Nov. 5-10 in Washington, D... | The company reacquired global rights to some of its drug candidates from AbbVie (NYSE: ABBV) and presented positive clinical data in a study involving omaveloxolone to treat Friedreich's ataxia. The American Society of Nephrology Annual Meeting, also known as Kidney Week, will take place from Nov. 5-10 in Washington, D... | The company reacquired global rights to some of its drug candidates from AbbVie (NYSE: ABBV) and presented positive clinical data in a study involving omaveloxolone to treat Friedreich's ataxia. The American Society of Nephrology Annual Meeting, also known as Kidney Week, will take place from Nov. 5-10 in Washington, D... |
24,851 | 2019-10-16 00:00:00 UTC | VTI, BRK.B, NEE, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/vti-brk.b-nee-abbv%3A-large-inflows-detected-at-etf-2019-10-16 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.9 billion dollar inflow -- that's a 2.4% increase week over week in outstanding units (from 791,002,930... | Among the largest underlying components of VTI, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is up about 0.2%, NextEra Energy Inc (Symbol: NEE) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the... | Among the largest underlying components of VTI, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is up about 0.2%, NextEra Energy Inc (Symbol: NEE) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the... | Among the largest underlying components of VTI, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is up about 0.2%, NextEra Energy Inc (Symbol: NEE) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs co... | Among the largest underlying components of VTI, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is up about 0.2%, NextEra Energy Inc (Symbol: NEE) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs co... |
24,852 | 2019-10-16 00:00:00 UTC | Should Investors Buy AbbVie Right Now for Its Dividend? | ABBV | https://www.nasdaq.com/articles/should-investors-buy-abbvie-right-now-for-its-dividend-2019-10-16 | null | null | Long-term dividend investors in the pharmaceutical sector have had quite a few high-quality stocks to invest in. One of these, however, seems to have fallen a little out of favor recently. Pharmaceutical giant AbbVie (NYSE: ABBV) has seen its shares fall significantly following news that it intended to acquire Botox de... | Other considerations While the consensus on Wall Street seems to be that Allergan brings plenty to the table in terms of stable revenue and drug candidates, the fact that AbbVie will end up paying more than $60 billion for the deal is what's worrying some investors. The company shows no signs that it's planning to stop... | Diving deeper into the Allergan acquisition Considering the sheer size of the deal, it’s worth taking some time to see exactly how the Allergan acquisition will change AbbVie's drug pipeline. AbbVie's chief executive also made sure to promise investors that the company would continue to grow its already strong dividend... | Other considerations While the consensus on Wall Street seems to be that Allergan brings plenty to the table in terms of stable revenue and drug candidates, the fact that AbbVie will end up paying more than $60 billion for the deal is what's worrying some investors. AbbVie's chief executive also made sure to promise in... | Besides these pipeline candidates, Allergan's Botox and implant products are also expected to remain solid revenue drivers for AbbVie once the merger comes together. Pharmaceutical giant AbbVie (NYSE: ABBV) has seen its shares fall significantly following news that it intended to acquire Botox developer Allergan (NYSE:... |
24,853 | 2019-10-16 00:00:00 UTC | Reata Pharmaceuticals Repositions Itself for Success | ABBV | https://www.nasdaq.com/articles/reata-pharmaceuticals-repositions-itself-for-success-2019-10-16 | null | null | It's been a busy October for Reata Pharmaceuticals (NASDAQ: RETA), which kicked things off Oct. 10 with the announcement that it would end its nine-year partnership with AbbVie (NYSE: ABBV). This move allows Reata to reclaim the exclusive rights to two drugs in late-stage clinical trials, as well as next-generation dru... | It's been a busy October for Reata Pharmaceuticals (NASDAQ: RETA), which kicked things off Oct. 10 with the announcement that it would end its nine-year partnership with AbbVie (NYSE: ABBV). Reata regains exclusive rights to drug candidates from AbbVie Reata is paying AbbVie $330 million to reacquire the rights to bard... | Reata regains exclusive rights to drug candidates from AbbVie Reata is paying AbbVie $330 million to reacquire the rights to bardoxolone methyl (bard), omav, and all next-generation Nrf2 activators. It's been a busy October for Reata Pharmaceuticals (NASDAQ: RETA), which kicked things off Oct. 10 with the announcement ... | Reata regains exclusive rights to drug candidates from AbbVie Reata is paying AbbVie $330 million to reacquire the rights to bardoxolone methyl (bard), omav, and all next-generation Nrf2 activators. The AbbVie license agreement hints that Reata will be raising additional large sums of capital, noting that if more than ... | Now that the positive results are known, Reata can use this capital to pay AbbVie. The AbbVie license agreement hints that Reata will be raising additional large sums of capital, noting that if more than $200 million is raised, Reata will pay AbbVie $25 million, to be deducted from the final milestone due in 2021. It's... |
24,854 | 2019-10-15 00:00:00 UTC | Here's Why Reata Pharmaceuticals Skyrocketed Higher Today | ABBV | https://www.nasdaq.com/articles/heres-why-reata-pharmaceuticals-skyrocketed-higher-today-2019-10-15 | null | null | What happened
Shares of Reata Pharmaceuticals (NASDAQ: RETA) are up 59% at 12:26 p.m. EDT, after the company released positive data for the midstage Moxie study of its drug candidate, omaveloxolone, in patients with a neuromuscular disease called Friedreich's ataxia.
As biotech investors have seen time and time again, ... | Now what In a well-timed move last week, Reata Pharmaceuticals agreed to pay $330 million to reacquire the rights to omaveloxolone and bardoxolone, a drug in the same Nrf2 activator drug class, from its partner AbbVie (NYSE: ABBV). Reata will also owe AbbVie single-digit, tiered royalties on sales of omaveloxolone and ... | Now what In a well-timed move last week, Reata Pharmaceuticals agreed to pay $330 million to reacquire the rights to omaveloxolone and bardoxolone, a drug in the same Nrf2 activator drug class, from its partner AbbVie (NYSE: ABBV). Reata will also owe AbbVie single-digit, tiered royalties on sales of omaveloxolone and ... | Now what In a well-timed move last week, Reata Pharmaceuticals agreed to pay $330 million to reacquire the rights to omaveloxolone and bardoxolone, a drug in the same Nrf2 activator drug class, from its partner AbbVie (NYSE: ABBV). Reata will also owe AbbVie single-digit, tiered royalties on sales of omaveloxolone and ... | Now what In a well-timed move last week, Reata Pharmaceuticals agreed to pay $330 million to reacquire the rights to omaveloxolone and bardoxolone, a drug in the same Nrf2 activator drug class, from its partner AbbVie (NYSE: ABBV). Reata will also owe AbbVie single-digit, tiered royalties on sales of omaveloxolone and ... |
24,855 | 2019-10-14 00:00:00 UTC | Health Care Sector Update for 10/14/2019: CTST,APYX,FLXN,AGN,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-10-14-2019%3A-ctstapyxflxnagnabbv-2019-10-14 | null | null | Top Health Care Stocks
JNJ -0.41%
PFE +0.43%
ABT +0.23%
MRK +0.43%
AMGN +1.26%
Health care stocks were slightly lower in late trade, with the NYSE Health Care Index and shares of health care companies in the S&P 500 as a group both slipping fractionally. The Nasdaq Biotechnology index was posting a nearly 0.3% advance.... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... |
24,856 | 2019-10-14 00:00:00 UTC | Health Care Sector Update for 10/14/2019: APYX,FLXN,AGN,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-10-14-2019%3A-apyxflxnagnabbv-2019-10-14 | null | null | Top Health Care Stocks
JNJ -0.29%
PFE +0.48%
ABT -0.04%
MRK +0.50%
AMGN +1.68%
Health care stocks were posting small gains this afternoon, with the NYSE Health Care Index slipping less than 0.1% while the shares of health care companies in the S&P 500 were up fractionally as a group. The Nasdaq Biotechnology index was ... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... | The Irish drugmaker said its shareholders have voted to approve its proposed $63 billion acquisition by American rival AbbVie (ABBV). Under terms of the proposed transaction announced in June, investors will 0.866 of an AbbVie shares and $120.30 in cash for each Allergan share, valuing the target company at $188.24 per... |
24,857 | 2019-10-13 00:00:00 UTC | 3 Top Healthcare Dividend Stocks That Are Great Picks for Retirees | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-dividend-stocks-that-are-great-picks-for-retirees-2019-10-13 | null | null | If you're near retirement or already retired, dividend stocks undoubtedly rank high on your list of investing alternatives. The healthcare sector is a great place to look for dividend stocks with aging demographics trends driving long-term growth.
But which healthcare dividend stocks provide high yields plus reasonable... | The primary concern that some investors have with AbbVie is that the company is highly dependent on sales of Humira, which now faces biosimilar competition in Europe and will do so in the bigger U.S. market beginning in 2023. Current blockbuster cancer drugs Imbruvica and Venclexta, both of which continue to generate s... | Here's why AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) stand out. AbbVie AbbVie's dividend yield of over 5.8% ranks as one of the highest among healthcare stocks. The primary concern that some investors have with AbbVie is that the company is highly dependent on sales of Humira, which no... | AbbVie AbbVie's dividend yield of over 5.8% ranks as one of the highest among healthcare stocks. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Here's why AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) stand out... | AbbVie AbbVie's dividend yield of over 5.8% ranks as one of the highest among healthcare stocks. Here's why AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) stand out. The primary concern that some investors have with AbbVie is that the company is highly dependent on sales of Humira, which no... |
24,858 | 2019-10-11 00:00:00 UTC | Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding? | ABBV | https://www.nasdaq.com/articles/will-the-pace-of-ma-pick-up-following-the-biotech-sectors-pounding-2019-10-11 | null | null | Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October, it's not all roses. ADC Therapeutics pulled its plans to list citing market conditions. German unicorn BioNTech raised ... | Following a five-month lull, AbbVie broke news in June of its proposed $63 billion acquisition of Allergan. However, Rubraca competes with three other drugs in the same class marketed by formidable competition: GlaxoSmithKline, AstraZeneca, and AbbVie. Neurocrine's partner AbbVie gained approval at the end of 2018 and ... | Following a five-month lull, AbbVie broke news in June of its proposed $63 billion acquisition of Allergan. However, Rubraca competes with three other drugs in the same class marketed by formidable competition: GlaxoSmithKline, AstraZeneca, and AbbVie. Neurocrine's partner AbbVie gained approval at the end of 2018 and ... | Following a five-month lull, AbbVie broke news in June of its proposed $63 billion acquisition of Allergan. However, Rubraca competes with three other drugs in the same class marketed by formidable competition: GlaxoSmithKline, AstraZeneca, and AbbVie. Neurocrine's partner AbbVie gained approval at the end of 2018 and ... | Following a five-month lull, AbbVie broke news in June of its proposed $63 billion acquisition of Allergan. However, Rubraca competes with three other drugs in the same class marketed by formidable competition: GlaxoSmithKline, AstraZeneca, and AbbVie. Neurocrine's partner AbbVie gained approval at the end of 2018 and ... |
24,859 | 2019-10-11 00:00:00 UTC | 3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-abbvie-chubb-and-applied-materials-2019-10-11 | null | null | Investors were willing to buy in for a second day in a row, encouraged the economy may get some help after all. Though it peeled back from its intraday high and volume was soft, the S&P 500 still ended Thursday’s action up 0.64%.
Source: Shutterstock
Netflix (NASDAQ:) led the charge, gaining nearly 5% after Goldman Sac... | None of those names are as compelling as stock charts of AbbVie (NYSE:), Applied Materials (NASDAQ:) and Chubb (NYSE:) are today. Last week and this week gave us more evidence that AbbVie is en route to the upper boundary of its trading range. AbbVie (ABBV) After an incredible 2017, AbbVie investors have experienced li... | None of those names are as compelling as stock charts of AbbVie (NYSE:), Applied Materials (NASDAQ:) and Chubb (NYSE:) are today. Last week and this week gave us more evidence that AbbVie is en route to the upper boundary of its trading range. AbbVie (ABBV) After an incredible 2017, AbbVie investors have experienced li... | None of those names are as compelling as stock charts of AbbVie (NYSE:), Applied Materials (NASDAQ:) and Chubb (NYSE:) are today. Last week and this week gave us more evidence that AbbVie is en route to the upper boundary of its trading range. AbbVie (ABBV) After an incredible 2017, AbbVie investors have experienced li... | None of those names are as compelling as stock charts of AbbVie (NYSE:), Applied Materials (NASDAQ:) and Chubb (NYSE:) are today. Last week and this week gave us more evidence that AbbVie is en route to the upper boundary of its trading range. AbbVie (ABBV) After an incredible 2017, AbbVie investors have experienced li... |
24,860 | 2019-10-10 00:00:00 UTC | Health Care Sector Update for 10/10/2019: IONS,RETA,ABBV,RARX,CGC,WEED.TO | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-10-10-2019%3A-ionsretaabbvrarxcgcweed.to-2019-10-10 | null | null | Top Health Care Stocks
JNJ -0.17%
PFE +0.21%
ABT +0.87%
MRK -0.48%
AMGN +0.88%
Health care stocks continue to post modest gains shortly before Thursday's closing bell, with the NYSE Health Care Index rising nearly 0.2% this afternoon while the shares of health care companies in the S&P 500 also were up more than 0.4% a... | (+) Reata Pharmaceuticals (RETA) jumped 13% on Thursday after the specialty drugmaker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment in 2019 and the remainder payable in Q2 2... | (+) Reata Pharmaceuticals (RETA) jumped 13% on Thursday after the specialty drugmaker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment in 2019 and the remainder payable in Q2 2... | (+) Reata Pharmaceuticals (RETA) jumped 13% on Thursday after the specialty drugmaker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment in 2019 and the remainder payable in Q2 2... | (+) Reata Pharmaceuticals (RETA) jumped 13% on Thursday after the specialty drugmaker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment in 2019 and the remainder payable in Q2 2... |
24,861 | 2019-10-10 00:00:00 UTC | Health Care Sector Update for 10/10/2019: RETA,ABBV,RARX,CGC | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-10-10-2019%3A-retaabbvrarxcgc-2019-10-10 | null | null | Top Health Care Stocks
JNJ +0.16%
PFE +0.24%
ABT +0.79%
MRK +0.10%
AMGN +0.90%
Health care stocks were posting modest gains, with the NYSE Health Care Index rising nearly 0.3% this afternoon while the shares of health care companies in the S&P 500 also were up almost 0.5% as a group. The Nasdaq Biotechnology index was ... | Among health care stocks moving on news: (+) Reata Pharmaceuticals (RETA) jumped 12% on Thursday after the specialty drug maker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment... | Among health care stocks moving on news: (+) Reata Pharmaceuticals (RETA) jumped 12% on Thursday after the specialty drug maker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment... | Among health care stocks moving on news: (+) Reata Pharmaceuticals (RETA) jumped 12% on Thursday after the specialty drug maker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment... | Among health care stocks moving on news: (+) Reata Pharmaceuticals (RETA) jumped 12% on Thursday after the specialty drug maker reacquired development and commercialization rights for its proprietary Nrf2 activator product platform from AbbVie (ABBV) for $330 million in cash, consisting of a $75 million upfront payment... |
24,862 | 2019-10-10 00:00:00 UTC | Notable Thursday Option Activity: ABBV, GILD, SWKS | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-abbv-gild-swks-2019-10-10 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 120,551 contracts has been traded thus far today, a contract volume which is representative of approximately 12.1 million underlying shares (given that ever... | Especially high volume was seen for the $70 strike call option expiring October 18, 2019, with 28,832 contracts trading so far today, representing approximately 2.9 million underlying shares of ABBV. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie ... | Especially high volume was seen for the $70 strike call option expiring October 18, 2019, with 28,832 contracts trading so far today, representing approximately 2.9 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $70 strike highlighted in orange: Gilead... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 120,551 contracts has been traded thus far today, a contract volume which is representative of approximately 12.1 million underlying shares (given that ever... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 120,551 contracts has been traded thus far today, a contract volume which is representative of approximately 12.1 million underlying shares (given that ever... |
24,863 | 2019-10-10 00:00:00 UTC | 3 Big Pharma Companies Driving Price Inflation | ABBV | https://www.nasdaq.com/articles/3-big-pharma-companies-driving-price-inflation-2019-10-10 | null | null | America is just about the only place on earth that allows drugmakers to set and raise the price of successful drugs to whatever the market will bear, and it shows. Between the fourth quarter of 2016 and the fourth quarter of 2018, the big biopharmaceutical companies below raised prices for these popular treatments at a... | European sales of Humira are already sinking in response to biosimilar competition, and AbbVie offset a lot of that loss by raising the list price in the U.S. 19.1% during the time frame studied. AbbVie: Humira AbbVie's flagship anti-inflammation injection, Humira, has proven itself useful many times over since launchi... | Running fewer clinical trials means an awful lot of Humira revenue reaches AbbVie's bottom line. Gilead Sciences: Genvoya and Truvada Unlike AbbVie, Gilead Sciences has been making unjustified increases to the prices of two HIV treatments, Truvada and Genvoya, several years ahead of their expected loss of exclusivity i... | Gilead Sciences: Genvoya and Truvada Unlike AbbVie, Gilead Sciences has been making unjustified increases to the prices of two HIV treatments, Truvada and Genvoya, several years ahead of their expected loss of exclusivity in the U.S. market. AbbVie: Humira AbbVie's flagship anti-inflammation injection, Humira, has prov... | Gilead Sciences: Genvoya and Truvada Unlike AbbVie, Gilead Sciences has been making unjustified increases to the prices of two HIV treatments, Truvada and Genvoya, several years ahead of their expected loss of exclusivity in the U.S. market. AbbVie: Humira AbbVie's flagship anti-inflammation injection, Humira, has prov... |
24,864 | 2019-10-08 00:00:00 UTC | Why AbbVie's Stock Jumped in September | ABBV | https://www.nasdaq.com/articles/why-abbvies-stock-jumped-in-september-2019-10-08 | null | null | What happened
Shares of biotech giant AbbVie (NYSE: ABBV) gained a healthy 15% in September, according to data from S&P Global Market Intelligence.
The spark? AbbVie's shares perked up after the company's presentation at the Morgan Stanley Healthcare Conference on Sept. 10. While the company didn't reveal anything new ... | What happened Shares of biotech giant AbbVie (NYSE: ABBV) gained a healthy 15% in September, according to data from S&P Global Market Intelligence. In short, AbbVie's flagship medication has been experiencing a sharper-than-expected drop in international sales following the introduction of biosimilars in Europe. As Gon... | Now what Can AbbVie's shares continue to rebound? So, as the fear over Humira's demise begins to fade and the positive impacts of this Allergen tie-up come into view, AbbVie's shares should begin to garner a more typical valuation for a top biotech. What happened Shares of biotech giant AbbVie (NYSE: ABBV) gained a hea... | So, as the fear over Humira's demise begins to fade and the positive impacts of this Allergen tie-up come into view, AbbVie's shares should begin to garner a more typical valuation for a top biotech. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to liste... | As Gonzalez noted during this latest investor presentation, though, AbbVie should be able to continue to post industry-leading levels of revenue and earnings growth well into the next decade, even after Humira loses patent protection in the United States. What happened Shares of biotech giant AbbVie (NYSE: ABBV) gained... |
24,865 | 2019-10-07 00:00:00 UTC | Why Johnson & Johnson Stock Is Not a Screaming Buy | ABBV | https://www.nasdaq.com/articles/why-johnson-johnson-stock-is-not-a-screaming-buy-2019-10-07 | null | null | Johnson & Johnson (NYSE:) stock has been a disappointing under-performer this year. While the S&P 500 is up nearly 18% year-to-date, JNJ stock is up just 5.7% (including dividends reinvested).
Source: Sundry Photography / Shutterstock.com
The company’s countless have impacted the JNJ stock price. But recent development... | Despite the opioid crisis weighing on shares, Credit Suisse’s is bullish on JNJ’s pharma growth prospects. He believes that once the company’s legal issues are quantified, the market will shift focus towards the pharma unit’s organic growth. While this would likely need to occur after the opioid suits are settled, in t... | With shares valued in line with big pharma peers, the stock does not appear to be a value play. JNJ Stock Fairly Valued Johnson & Johnson stock trades in line with its peers. Consumer products companies like Procter & Gamble (NYSE:) trade at even higher EBITDA multiples (19.4x). | JNJ Stock Fairly Valued Johnson & Johnson stock trades in line with its peers. Here are the valuation metrics for JNJ’s myriad of big pharma peers: AstraZeneca PLC (NYSE:): Forward P/E of 10.6; EV/EBITDA of 11.5 Bristol Myers Squibb (NYSE:): Forward P/E of 8.6; EV/EBITDA of 10.4 GlaxoSmithKline PLC (NYSE:): Forward P/E... | Johnson & Johnson (NYSE:) stock has been a disappointing under-performer this year. Dividend aristocrat status provides a floor in the Johnson & Johnson stock price. While this would likely need to occur after the opioid suits are settled, in the longer term, a “trivestiture” could unlock value in the JNJ stock price. |
24,866 | 2019-10-06 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-right-now-2019-10-06 | null | null | There's just something satisfying about a stock that pays you to own it. And that's exactly what dividend stocks do. Of course, some of them are better than others.
Three top dividend stocks that investors can buy right now are AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Brookfield Infrastructure Partners (NYSE: BIP). Her... | Should you worry about AbbVie's continued ability to sustain its dividend, given that its top-selling drug Humira faces competition from biosimilars and that the company is taking on debt to fund its planned acquisition of Allergan? Thanks to growing sales for Rinvoq and Skyrizi, along with sustained momentum for its o... | Three top dividend stocks that investors can buy right now are AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Brookfield Infrastructure Partners (NYSE: BIP). The buyout of Allergan shouldn't hider AbbVie's ability to continue paying solid dividends, and the purchase will help reduce its reliance on Humira. AbbVie AbbVie pays... | Three top dividend stocks that investors can buy right now are AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Brookfield Infrastructure Partners (NYSE: BIP). Should you worry about AbbVie's continued ability to sustain its dividend, given that its top-selling drug Humira faces competition from biosimilars and that the compan... | AbbVie AbbVie pays a dividend that currently yields 5.72%. Three top dividend stocks that investors can buy right now are AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Brookfield Infrastructure Partners (NYSE: BIP). Should you worry about AbbVie's continued ability to sustain its dividend, given that its top-selling drug Hu... |
24,867 | 2019-10-03 00:00:00 UTC | 2 Great Stocks You Can Buy on Sale | ABBV | https://www.nasdaq.com/articles/2-great-stocks-you-can-buy-on-sale-2019-10-03 | null | null | The stock market's recent volatility shouldn't concern investors with a long-term outlook. In fact, it's probably a blessing in disguise for the buy-and-hold crowd. Several great stocks, after all, are now trading at attractive valuations.
In the beaten-up healthcare sector, for instance, AbbVie (NYSE: ABBV) and Amgen... | AbbVie has built out a solid portfolio of next-generation products and it recently inked a merger agreement with Allergan (NYSE: AGN) that will immediately soften the blow from Humira's demise. In the beaten-up healthcare sector, for instance, AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) stand out as two outstanding bu... | In the beaten-up healthcare sector, for instance, AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) stand out as two outstanding buys following their poor showing through the first nine months of 2019. AbbVie: Buy the fear AbbVie's shares are shrouded in fear right now. AbbVie has built out a solid portfolio of next-generat... | Apart from AbbVie's impressive portfolio of newer growth products, there are two more compelling reasons to consider buying this elite biotech stock soon. In the beaten-up healthcare sector, for instance, AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) stand out as two outstanding buys following their poor showing through... | Apart from AbbVie's impressive portfolio of newer growth products, there are two more compelling reasons to consider buying this elite biotech stock soon. In the beaten-up healthcare sector, for instance, AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) stand out as two outstanding buys following their poor showing through... |
24,868 | 2019-10-03 00:00:00 UTC | 3 Stocks to Supplement Your Social Security Income | ABBV | https://www.nasdaq.com/articles/3-stocks-to-supplement-your-social-security-income-2019-10-03 | null | null | In any discussion about investing in retirement, conventional wisdom contends that bonds are the way to go. They fluctuate in value far less than the average stock and payout steady interest payments. Fixed-income investments like bonds can be a great way to generate extra cash to supplement Social Security and pay the... | Aging autoimmune disease treatment Humira losing some of its patent protection explains some of the price drop, as does AbbVie's proposed acquisition of Botox maker Allergan for $63 billion to diversify its sales base and boost cash flow. Three that look particularly attractive for retirees are AbbVie (NYSE: ABBV), Phi... | The two maturing pharmaceutical businesses generate plenty of cash flow (a combined $19 billion in 2018) to pay down the debt financing, and AbbVie thinks an additional $2 billion in cost savings can eventually be found post-merger. AbbVie's current free cash flow (basic profits after operating and capital expenditures... | AbbVie's current free cash flow (basic profits after operating and capital expenditures are paid for) handily covers the current payout of $4.28 per share every year, good for a current yield of 5.7%. Diversifying the number of stocks invested in is key to mitigating risk, but AbbVie, Phillips 66, and Store Capital are... | The two maturing pharmaceutical businesses generate plenty of cash flow (a combined $19 billion in 2018) to pay down the debt financing, and AbbVie thinks an additional $2 billion in cost savings can eventually be found post-merger. Three that look particularly attractive for retirees are AbbVie (NYSE: ABBV), Phillips ... |
24,869 | 2019-10-03 00:00:00 UTC | 10 Insider Trading Stocks: What Execs and Directors Are Buying | ABBV | https://www.nasdaq.com/articles/10-insider-trading-stocks%3A-what-execs-and-directors-are-buying-2019-10-03 | null | null | When investors think of "insider trading," they might think of the kind of behavior to which ex-Rep. Chris Collins recently pleaded guilty. In that case, Collins used material, nonpublic information he gained from his seat on a biotechnology company's board to tip off his son and fiancée's father, who were able to sell... | SEE ALSO: 5 REITs You Can Buy and Hold for Decades AbbVie Market value: $106.6 billion Notable recent insider purchases: $10.4 million AbbVie (ABBV, $72.13) is a leading pharmaceutical company. Humira accounted for $19.1 billion in 2018 -nearly 60% of AbbVie's sales that year - but faces increasing competition from low... | SEE ALSO: 5 REITs You Can Buy and Hold for Decades AbbVie Market value: $106.6 billion Notable recent insider purchases: $10.4 million AbbVie (ABBV, $72.13) is a leading pharmaceutical company. Humira accounted for $19.1 billion in 2018 -nearly 60% of AbbVie's sales that year - but faces increasing competition from low... | SEE ALSO: 5 REITs You Can Buy and Hold for Decades AbbVie Market value: $106.6 billion Notable recent insider purchases: $10.4 million AbbVie (ABBV, $72.13) is a leading pharmaceutical company. Humira accounted for $19.1 billion in 2018 -nearly 60% of AbbVie's sales that year - but faces increasing competition from low... | SEE ALSO: 5 REITs You Can Buy and Hold for Decades AbbVie Market value: $106.6 billion Notable recent insider purchases: $10.4 million AbbVie (ABBV, $72.13) is a leading pharmaceutical company. Humira accounted for $19.1 billion in 2018 -nearly 60% of AbbVie's sales that year - but faces increasing competition from low... |
24,870 | 2019-10-02 00:00:00 UTC | Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock | ABBV | https://www.nasdaq.com/articles/forget-vertex-pharmaceuticals-crispr-therapeutics-is-a-better-biotech-growth-stock-2019-10 | null | null | Both CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are biotech stocks that have plenty of positive things going for them. In fact, these companies happen to be partners in an ongoing project to treat genetic diseases via gene-editing technologies. Yet despite this commonality, these stock... | Besides Vertex, the $110 billion pharma giant AbbVie (NYSE: ABBV) is also a player (although some of its recent clinical trial data has been mediocre in comparison to Vertex's results), and Gilead Sciences (NASDAQ: GILD) has a cystic fibrosis drug, Cayston, that Vertex has to compete with as well. While the much larger... | Besides Vertex, the $110 billion pharma giant AbbVie (NYSE: ABBV) is also a player (although some of its recent clinical trial data has been mediocre in comparison to Vertex's results), and Gilead Sciences (NASDAQ: GILD) has a cystic fibrosis drug, Cayston, that Vertex has to compete with as well. CRISPR's potential so... | Besides Vertex, the $110 billion pharma giant AbbVie (NYSE: ABBV) is also a player (although some of its recent clinical trial data has been mediocre in comparison to Vertex's results), and Gilead Sciences (NASDAQ: GILD) has a cystic fibrosis drug, Cayston, that Vertex has to compete with as well. The gene-editing mark... | Besides Vertex, the $110 billion pharma giant AbbVie (NYSE: ABBV) is also a player (although some of its recent clinical trial data has been mediocre in comparison to Vertex's results), and Gilead Sciences (NASDAQ: GILD) has a cystic fibrosis drug, Cayston, that Vertex has to compete with as well. Focusing on genetic d... |
24,871 | 2019-10-01 00:00:00 UTC | 10 Medical Marijuana Stocks to Cure Your Portfolio | ABBV | https://www.nasdaq.com/articles/10-medical-marijuana-stocks-to-cure-your-portfolio-2019-10-01 | null | null | [Editor’s note: “10 Medical Marijuana Stocks to Cure Your Portfolio” was previously published in August 2019. It has since been updated to include the most relevant information available.]
Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, toward l... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, AbbVie maintains some botani... |
24,872 | 2019-10-01 00:00:00 UTC | 4 Healthcare Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/4-healthcare-stocks-to-buy-now-2019-10-01 | null | null | U.S. equities are pushing higher this week thanks to — you guessed it — hopes of a U.S.-China trade deal. The White House has somewhat denied rumors from Friday that President Donald Trump was considering delisting Chinese companies from American stock changes.
JPMorgan analyst also raised the firm’s price target on Ap... | This upgrade is based on expectations that AbbVie will extract significant shareholder value from its purchase of Allergan. AbbVie (ABBV) AbbVie (NYSE:) shares are on the mend, climbing back up and over its 200-day moving average for the first time since August 2018. The White House has somewhat denied rumors from Frid... | AbbVie (ABBV) AbbVie (NYSE:) shares are on the mend, climbing back up and over its 200-day moving average for the first time since August 2018. This upgrade is based on expectations that AbbVie will extract significant shareholder value from its purchase of Allergan. Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE:) ... | AbbVie (ABBV) AbbVie (NYSE:) shares are on the mend, climbing back up and over its 200-day moving average for the first time since August 2018. This upgrade is based on expectations that AbbVie will extract significant shareholder value from its purchase of Allergan. Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE:) ... | AbbVie (ABBV) AbbVie (NYSE:) shares are on the mend, climbing back up and over its 200-day moving average for the first time since August 2018. This upgrade is based on expectations that AbbVie will extract significant shareholder value from its purchase of Allergan. Here are four stocks to consider. |
24,873 | 2019-10-01 00:00:00 UTC | 3 Big Stock Charts for Tuesday: AbbVie, S&P Global and FleetCor Technologies | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-abbvie-sp-global-and-fleetcor-technologies-2019-10-01 | null | null | The market kicked off the new trading week in a better mood than it ended the old though, although Monday’s 0.5% gain for the S&P 500 wasn’t exactly game-changing. Volume was light, and we’re still within reach of a key technical breakdown.
Source: Shutterstock
Apple (NASDAQ:) did more than its fair share of heavy lift... | • The trading range that’s been guiding ABBV stock lower since early last year is still intact, although AbbVie is testing that upper boundary at this time. As for names worth a trading-minded look headed into Tuesday’s session, though, take a look at the stock charts of AbbVie (NYSE:), S&P Global (NYSE:) and FleetCor ... | As for names worth a trading-minded look headed into Tuesday’s session, though, take a look at the stock charts of AbbVie (NYSE:), S&P Global (NYSE:) and FleetCor Technologies (NYSE:). AbbVie (ABBV) The last time AbbVie was under the trading microscope , it was in a downtrend, but finding support at a couple of differe... | As for names worth a trading-minded look headed into Tuesday’s session, though, take a look at the stock charts of AbbVie (NYSE:), S&P Global (NYSE:) and FleetCor Technologies (NYSE:). AbbVie (ABBV) The last time AbbVie was under the trading microscope , it was in a downtrend, but finding support at a couple of differe... | As for names worth a trading-minded look headed into Tuesday’s session, though, take a look at the stock charts of AbbVie (NYSE:), S&P Global (NYSE:) and FleetCor Technologies (NYSE:). AbbVie (ABBV) The last time AbbVie was under the trading microscope , it was in a downtrend, but finding support at a couple of differe... |
24,874 | 2019-10-01 00:00:00 UTC | 2 Reasons Why 1 Top Analyst Thinks AbbVie Could Soar Nearly 20% | ABBV | https://www.nasdaq.com/articles/2-reasons-why-1-top-analyst-thinks-abbvie-could-soar-nearly-20-2019-10-01 | null | null | Several Wall Street analysts expressed skepticism when AbbVie (NYSE: ABBV) announced its planned $63 billion acquisition of Allergan (NYSE: AGN) in June. This negativity contributed to an absolutely dismal performance for AbbVie so far in 2019, with its shares dropping more than 30% at one point.
But at least one analy... | Several Wall Street analysts expressed skepticism when AbbVie (NYSE: ABBV) announced its planned $63 billion acquisition of Allergan (NYSE: AGN) in June. This negativity contributed to an absolutely dismal performance for AbbVie so far in 2019, with its shares dropping more than 30% at one point. But at least one analy... | But at least one analyst now thinks that AbbVie looks like a great pharma stock to buy. The Allergan acquisition isn't such a bad idea after all Baum wrote to investors that Citi believes "AbbVie will extract significant shareholder value from Allergan's franchises." AbbVie expects that its acquisition of Allergan will... | Citigroup's Andrew Baum recently upgraded AbbVie from a neutral rating to a buy rating and set a one-year price target that's nearly 20% above AbbVie's current share price. The Allergan acquisition isn't such a bad idea after all Baum wrote to investors that Citi believes "AbbVie will extract significant shareholder va... | The Allergan acquisition isn't such a bad idea after all Baum wrote to investors that Citi believes "AbbVie will extract significant shareholder value from Allergan's franchises." Rinvoq and Skyrizi aren't getting enough respect Two other core components to AbbVie's strategy to deal with its Humira issue are the compan... |
24,875 | 2019-09-30 00:00:00 UTC | ABBV: Insiders vs. Shorts | ABBV | https://www.nasdaq.com/articles/abbv%3A-insiders-vs.-shorts-2019-09-30 | null | null | The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc (Symbol: ABBV) is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to... | AbbVie Inc (Symbol: ABBV) has something relatively rare for a stock with this much short interest, that being insiders taking the other side of the trade. In recent trading, shares of AbbVie Inc (Symbol: ABBV) were changing hands at $76.01/share. The most recent short interest data was recently released for the 04/15/2... | The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc (Symbol: ABBV) is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,8... | In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,807 shares, which compares to the average daily trading volume of just 4,952,645 shares, for a "days to cover" ratio of 5.57. At the present levels of short interest, if from this point forward every single A... | In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,807 shares, which compares to the average daily trading volume of just 4,952,645 shares, for a "days to cover" ratio of 5.57. At the present levels of short interest, if from this point forward every single A... |
24,876 | 2019-09-30 00:00:00 UTC | 3 Dividend Stocks That Are Perfect for Retirement | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-are-perfect-for-retirement-2019-09-30 | null | null | Investors in retirement or close to it often look to dividend stocks to provide a steady source of income without having to sell shares when the market is on a downswing. But retirees should be planning an investment strategy that will support them into their 90s, which means that the plan will need to include growth t... | Three stocks that have a dividend yield greater than today's paltry interest rates on savings accounts or government bonds and can protect your nest egg from the erosion of inflation are Prologis (NYSE: PLD), STORE Capital (NYSE: STOR), and AbbVie (NYSE: ABBV). Abbvie Investors frequently turn to the stocks of major dr... | AbbVie stock has been under pressure since early 2018, and the biggest issue is biosimilar competition for immunology drug Humira, the world's top-selling drug and the source of 59% of the company's sales. Three stocks that have a dividend yield greater than today's paltry interest rates on savings accounts or governme... | AbbVie won't have the same level of growth that the other two picks will have, but the market is giving us an opportunity for a generous yield along with some capital gains as investors come to appreciate the strengths of the new, combined company, which include modest growth in the long term. Jim Crumly owns shares of... | Three stocks that have a dividend yield greater than today's paltry interest rates on savings accounts or government bonds and can protect your nest egg from the erosion of inflation are Prologis (NYSE: PLD), STORE Capital (NYSE: STOR), and AbbVie (NYSE: ABBV). Abbvie Investors frequently turn to the stocks of major dr... |
24,877 | 2019-09-29 00:00:00 UTC | FTC Seeks Addl Information On AbbVie-Allergan $63 Bln Deal | ABBV | https://www.nasdaq.com/articles/ftc-seeks-addl-information-on-abbvie-allergan-%2463-bln-deal-2019-09-29 | null | null | (RTTNews) - The U.S. Federal Trade Commission has requested for additional information from AbbVie Inc (ABBV) and Allergan Plc (AGN) on their $63 billion deal, the companies said.
The Second Request extends the waiting period under the HSR Act until 30 days after both Allergan and AbbVie have substantially complied wit... | (RTTNews) - The U.S. Federal Trade Commission has requested for additional information from AbbVie Inc (ABBV) and Allergan Plc (AGN) on their $63 billion deal, the companies said. In June 2019, AbbVie agreed to acquire Allergan in a cash and stock transaction with an equity value of about $63 billion. The Second Reques... | The Second Request extends the waiting period under the HSR Act until 30 days after both Allergan and AbbVie have substantially complied with the Second Request. (RTTNews) - The U.S. Federal Trade Commission has requested for additional information from AbbVie Inc (ABBV) and Allergan Plc (AGN) on their $63 billion deal... | (RTTNews) - The U.S. Federal Trade Commission has requested for additional information from AbbVie Inc (ABBV) and Allergan Plc (AGN) on their $63 billion deal, the companies said. The Second Request extends the waiting period under the HSR Act until 30 days after both Allergan and AbbVie have substantially complied wit... | (RTTNews) - The U.S. Federal Trade Commission has requested for additional information from AbbVie Inc (ABBV) and Allergan Plc (AGN) on their $63 billion deal, the companies said. The Second Request extends the waiting period under the HSR Act until 30 days after both Allergan and AbbVie have substantially complied wit... |
24,878 | 2019-09-27 00:00:00 UTC | Health Care Sector Update for 09/27/2019: HSGX, PRPO, ABBV, JNJ, ABT, PFE, MRK, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-09-27-2019%3A-hsgx-prpo-abbv-jnj-abt-pfe-mrk-amgn-2019-09-27 | null | null | Top Health Care Stocks:
JNJ: +0.12%
PFE: +0.61%
ABT: Flat
MRK: +0.44%
AMGN: +0.20%
Top health care stocks were flat to higher pre-market Friday.
Stocks moving on news include:
(-) Histogenics (HSGX), which was down more than 9% as its stockholders approved all proposals related to its proposed combination with Ocugen.
... | In other sector news: (+) AbbVie (ABBV) was marginally gaining as the Food and Drug Administration has approved the company's drug Mavyret to shorten the duration of treatment of chronic hepatitis C (HCV) patients across all genotypes. Top health care stocks were flat to higher pre-market Friday. (+) Precipio (PRPO) wa... | In other sector news: (+) AbbVie (ABBV) was marginally gaining as the Food and Drug Administration has approved the company's drug Mavyret to shorten the duration of treatment of chronic hepatitis C (HCV) patients across all genotypes. Top Health Care Stocks: Top health care stocks were flat to higher pre-market Friday... | In other sector news: (+) AbbVie (ABBV) was marginally gaining as the Food and Drug Administration has approved the company's drug Mavyret to shorten the duration of treatment of chronic hepatitis C (HCV) patients across all genotypes. Top health care stocks were flat to higher pre-market Friday. Stocks moving on news ... | In other sector news: (+) AbbVie (ABBV) was marginally gaining as the Food and Drug Administration has approved the company's drug Mavyret to shorten the duration of treatment of chronic hepatitis C (HCV) patients across all genotypes. Top health care stocks were flat to higher pre-market Friday. Stocks moving on news ... |
24,879 | 2019-09-26 00:00:00 UTC | AbbVie Receives FDA Approval Of MAVYRET | ABBV | https://www.nasdaq.com/articles/abbvie-receives-fda-approval-of-mavyret-2019-09-26 | null | null | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6.
In August 2017, MAVYRET... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6. Glecaprevir was discove... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6. Glecaprevir was discove... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6. Glecaprevir was discove... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6. Glecaprevir was discove... |
24,880 | 2019-09-26 00:00:00 UTC | SPDR S&P Dividend ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/spdr-sp-dividend-etf-experiences-big-outflow-2019-09-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $56.3 million dollar outflow -- that's a 0.3% decrease week over week (from 184,700,000 to 184,150,000). Among the l... | Among the largest underlying components of SDY, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.7%, Realty Income Corp (Symbol: O) is up about 0.6%, and Cardinal Health, Inc. (Symbol: CAH) is lower by about 0.4%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year ... | Among the largest underlying components of SDY, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.7%, Realty Income Corp (Symbol: O) is up about 0.6%, and Cardinal Health, Inc. (Symbol: CAH) is lower by about 0.4%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year ... | Among the largest underlying components of SDY, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.7%, Realty Income Corp (Symbol: O) is up about 0.6%, and Cardinal Health, Inc. (Symbol: CAH) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of SDY, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.7%, Realty Income Corp (Symbol: O) is up about 0.6%, and Cardinal Health, Inc. (Symbol: CAH) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
24,881 | 2019-09-24 00:00:00 UTC | Better Buy: AbbVie vs. Eli Lilly | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-eli-lilly-2019-09-24 | null | null | AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. These two pharma giants have generated total returns on capital (including dividends) of 52% and 97%, respectively, over the last five years.
Nonetheless, AbbVie and Lilly have both ru... | On the plus side of the ledger, AbbVie has significantly beefed up its product portfolio with the approval of three potential megablockbusters: Skyrizi for psoriasis, Rinvoq for rheumatoid arthritis, and Orilissa for uterine fibroids. AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and grow... | AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. AbbVie's strengths and weaknesses AbbVie has grown its top line and dividend at industry-leading levels ever since Abbott Laboratories spun the biotech off into a separate entity in 201... | AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. Nonetheless, AbbVie and Lilly have both run into trouble in 2019 due to a mix of company-specific issues and industrywide headwinds. AbbVie's strengths and weaknesses AbbVie has grown i... | AbbVie's blood cancer medication Imbruvica is staring down a slew of competitive threats. AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. Nonetheless, AbbVie and Lilly have both run into trouble in 2019 due to a mix of company-specif... |
24,882 | 2019-09-24 00:00:00 UTC | Healthy Dividend Aristocrats: 6 Great Health-Care Dividend Stocks | ABBV | https://www.nasdaq.com/articles/healthy-dividend-aristocrats%3A-6-great-health-care-dividend-stocks-2019-09-24 | null | null | Sluggish global growth, the U.S. trade war with China and a stock market that's up only about 2% over the past year have some investors thinking about playing defense. And few equities are better at adding ballast to a portfolio than the rock-solid dividend growth stocks in the Dividend Aristocrats - companies in the S... | SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained Abbott Laboratories Market value: $147.0 billion Dividend yield: 1.5% Consecutive annual dividend increases: 47 Analysts' opinion: 11 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell Abbott Laboratories (ABT, $83.16) actually split into a pair ... | SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained Abbott Laboratories Market value: $147.0 billion Dividend yield: 1.5% Consecutive annual dividend increases: 47 Analysts' opinion: 11 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell Abbott Laboratories (ABT, $83.16) actually split into a pair ... | SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained Abbott Laboratories Market value: $147.0 billion Dividend yield: 1.5% Consecutive annual dividend increases: 47 Analysts' opinion: 11 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell Abbott Laboratories (ABT, $83.16) actually split into a pair ... | SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained Abbott Laboratories Market value: $147.0 billion Dividend yield: 1.5% Consecutive annual dividend increases: 47 Analysts' opinion: 11 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell Abbott Laboratories (ABT, $83.16) actually split into a pair ... |
24,883 | 2019-09-23 00:00:00 UTC | The Math Shows XLG Can Go To $237 | ABBV | https://www.nasdaq.com/articles/the-math-shows-xlg-can-go-to-%24237-2019-09-23 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 500— Top 50 ETF (Sy... | Below is a twelve month price history chart comparing the stock performance of JNJ, ABBV, and BAC: Combined, JNJ, ABBV, and BAC represent 5.65% of the Invesco S&P 500— Top 50 ETF. Three of XLG's underlying holdings with notable upside to their analyst target prices are Johnson & Johnson (Symbol: JNJ), AbbVie Inc (Symbo... | Three of XLG's underlying holdings with notable upside to their analyst target prices are Johnson & Johnson (Symbol: JNJ), AbbVie Inc (Symbol: ABBV), and Bank of America Corp (Symbol: BAC). Similarly, ABBV has 12.49% upside from the recent share price of $72.39 if the average analyst target price of $81.43/share is rea... | Similarly, ABBV has 12.49% upside from the recent share price of $72.39 if the average analyst target price of $81.43/share is reached, and analysts on average are expecting BAC to reach a target price of $33.25/share, which is 12.37% above the recent price of $29.59. Three of XLG's underlying holdings with notable ups... | Below is a twelve month price history chart comparing the stock performance of JNJ, ABBV, and BAC: Combined, JNJ, ABBV, and BAC represent 5.65% of the Invesco S&P 500— Top 50 ETF. Three of XLG's underlying holdings with notable upside to their analyst target prices are Johnson & Johnson (Symbol: JNJ), AbbVie Inc (Symbo... |
24,884 | 2019-09-21 00:00:00 UTC | 2 Pharma Stocks You Should Buy Now | ABBV | https://www.nasdaq.com/articles/2-pharma-stocks-you-should-buy-now-2019-09-21 | null | null | The pharmaceutical industry is important for one simple reason: we are all, at some point, in need of medical treatment, and the amount of money that is spent on drugs continues to increase. Until we stumble upon a way to eradicate illnesses altogether, that isn't going to change. Though we can't escape from this sad r... | After ranking third on the list of world's top selling drugs last year, Keytruda is projected to take the top spot by 2024 as the current top selling medicine -- AbbVie's (NYSE: ABBV) Humira -- faces stiff competition from biosimilars in Europe. The pharmaceutical industry is important for one simple reason: we are all... | After ranking third on the list of world's top selling drugs last year, Keytruda is projected to take the top spot by 2024 as the current top selling medicine -- AbbVie's (NYSE: ABBV) Humira -- faces stiff competition from biosimilars in Europe. Image source: Getty Images Dominating the cystic fibrosis market Vertex' a... | After ranking third on the list of world's top selling drugs last year, Keytruda is projected to take the top spot by 2024 as the current top selling medicine -- AbbVie's (NYSE: ABBV) Humira -- faces stiff competition from biosimilars in Europe. The pharma company's top selling product is approved for a range of cancer... | After ranking third on the list of world's top selling drugs last year, Keytruda is projected to take the top spot by 2024 as the current top selling medicine -- AbbVie's (NYSE: ABBV) Humira -- faces stiff competition from biosimilars in Europe. Meanwhile, Merck's Keytruda is on pace to become the world's best selling ... |
24,885 | 2019-09-18 00:00:00 UTC | An Investor's Guide to Disrupting Drugmakers | ABBV | https://www.nasdaq.com/articles/an-investors-guide-to-disrupting-drugmakers-2019-09-18 | null | null | When you need a medication that's insanely expensive, what choice do you have other than to grin and bear it?
Make it yourself, apparently.
A group in Oakland, California, the Open Insulin Project, is trying to do just that for diabetics who can't afford their medication.
In theory, it's not that hard to produce insuli... | The price of hepatitis C drugs from Gilead Sciences (NASDAQ: GILD), for example, has come down substantially as AbbVie (NYSE: ABBV) has gained approval for competing regimens. For basic insulin, insurance companies and pharmacy benefit managers have been able to pit insulin makers -- Eli Lilly (NYSE: LLY), Sanofi (NASD... | The price of hepatitis C drugs from Gilead Sciences (NASDAQ: GILD), for example, has come down substantially as AbbVie (NYSE: ABBV) has gained approval for competing regimens. For example, U.S. sales of Novo Nordisk's human insulin were down 31% at constant exchange rates in the first half of the year, although the com... | The price of hepatitis C drugs from Gilead Sciences (NASDAQ: GILD), for example, has come down substantially as AbbVie (NYSE: ABBV) has gained approval for competing regimens. For basic insulin, insurance companies and pharmacy benefit managers have been able to pit insulin makers -- Eli Lilly (NYSE: LLY), Sanofi (NASD... | The price of hepatitis C drugs from Gilead Sciences (NASDAQ: GILD), for example, has come down substantially as AbbVie (NYSE: ABBV) has gained approval for competing regimens. For basic insulin, insurance companies and pharmacy benefit managers have been able to pit insulin makers -- Eli Lilly (NYSE: LLY), Sanofi (NASD... |
24,886 | 2019-09-15 00:00:00 UTC | What Is a Dividend Aristocrat? | ABBV | https://www.nasdaq.com/articles/what-is-a-dividend-aristocrat-2019-09-15 | null | null | Millions of investors own stocks that regularly pay out dividends of varying amounts per share, but few are familiar with an elite class of dividend stocks known as Dividend Aristocrats.
In this article, we'll break down exactly why Dividend Aristocrats are so attractive to investors and share a few aristocrat stocks t... | These are companies that have been around for decades, perhaps even centuries, and can afford to let go of some of their liquid capital each quarter without needing to immediately reinvest it in the business to fund things like research, development, marketing, or paying off debt. Rather than reinvesting extra capital ... | Millions of investors own stocks that regularly pay out dividends of varying amounts per share, but few are familiar with an elite class of dividend stocks known as Dividend Aristocrats. Why Dividend Aristocrats make strong investments Not just any company is capable of increasing its dividend for 25-plus years. Consid... | Millions of investors own stocks that regularly pay out dividends of varying amounts per share, but few are familiar with an elite class of dividend stocks known as Dividend Aristocrats. In other words, a company doesn't become successful because it offers dividends; a company offers dividends because it is successful.... | What is a dividend? What are Dividend Aristocrats? But Dividend Aristocrats are different. |
24,887 | 2019-09-12 00:00:00 UTC | Anxious About AbbVie? Here Are 4 Things You Should Know | ABBV | https://www.nasdaq.com/articles/anxious-about-abbvie-here-are-4-things-you-should-know-2019-09-12 | null | null | AbbVie (NYSE: ABBV) went from having a great year in 2017 to having a mediocre one in 2018 to having a downright dismal one so far in 2019. Investors have been worried for years about what would happen when the company's top-selling drug, Humira, faced biosimilar competition. That day has arrived -- and many investors ... | AbbVie CEO Rick Gonzalez stated at this week's Morgan Stanley Global Healthcare Conference that the company looked into this thoroughly before making a decision. AbbVie (NYSE: ABBV) went from having a great year in 2017 to having a mediocre one in 2018 to having a downright dismal one so far in 2019. Today, there are e... | The Allergan acquisition won't be an albatross around AbbVie's neck Almost immediately after AbbVie announced its plans to acquire Allergan (NYSE: AGN), the deal was heralded as a $63 billion mistake. Actually, my view is that the Allergan acquisition won't be an albatross around AbbVie's neck at all. AbbVie (NYSE: ABB... | The Allergan acquisition won't be an albatross around AbbVie's neck Almost immediately after AbbVie announced its plans to acquire Allergan (NYSE: AGN), the deal was heralded as a $63 billion mistake. He also noted that while AbbVie's parent company, Abbott Labs, co-promoted Purdue Pharma's Oxycontin in the past, AbbVi... | Today, there are even more things investors are concerned about with AbbVie in addition to Humira. AbbVie (NYSE: ABBV) went from having a great year in 2017 to having a mediocre one in 2018 to having a downright dismal one so far in 2019. If you're among those anxious about AbbVie, here are four things you should know. |
24,888 | 2019-09-11 00:00:00 UTC | Noteworthy Wednesday Option Activity: LAD, NEM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-lad-nem-abbv-2019-09-11 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lithia Motors Inc (Symbol: LAD), where a total volume of 782 contracts has been traded thus far today, a contract volume which is representative of approximately 78,200 underlying shares (given that eve... | Especially high volume was seen for the $70 strike call option expiring October 18, 2019, with 2,803 contracts trading so far today, representing approximately 280,300 underlying shares of ABBV. Below is a chart showing NEM's trailing twelve month trading history, with the $32.12 strike highlighted in orange: And AbbVi... | Below is a chart showing NEM's trailing twelve month trading history, with the $32.12 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,328 contracts thus far today. That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 40... | Below is a chart showing NEM's trailing twelve month trading history, with the $32.12 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,328 contracts thus far today. That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 40... | Below is a chart showing ABBV's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for LAD options, NEM options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing NEM's trailing twelve month trading history, with the $... |
24,889 | 2019-09-10 00:00:00 UTC | Notable ETF Outflow Detected - ACWI, HON, LLY, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-acwi-hon-lly-abbv-2019-09-10 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $58.9 million dollar outflow -- that's a 0.5% decrease week over week (from 146,800,000 to 146,000,000). Among the ... | Among the largest underlying components of ACWI, in trading today Honeywell International Inc (Symbol: HON) is down about 1.1%, Lilly (Eli) & Co (Symbol: LLY) is off about 2.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows th... | Among the largest underlying components of ACWI, in trading today Honeywell International Inc (Symbol: HON) is down about 1.1%, Lilly (Eli) & Co (Symbol: LLY) is off about 2.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows th... | Among the largest underlying components of ACWI, in trading today Honeywell International Inc (Symbol: HON) is down about 1.1%, Lilly (Eli) & Co (Symbol: LLY) is off about 2.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs co... | Among the largest underlying components of ACWI, in trading today Honeywell International Inc (Symbol: HON) is down about 1.1%, Lilly (Eli) & Co (Symbol: LLY) is off about 2.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs co... |
24,890 | 2019-09-10 00:00:00 UTC | 10 Healthcare Stocks to Buy Despite the Headlines | ABBV | https://www.nasdaq.com/articles/10-healthcare-stocks-to-buy-despite-the-headlines-2019-09-10 | null | null | The past several weeks have been raucous ones for all stocks, but particularly wild ones for healthcare stocks. Not only is the future of the nation’s healthcare market in flux, drug companies are facing an inordinate degree of litigation, and biopharma names have dished out plenty of R&D updates … some good, some bad.... | AbbVie (ABBV) Source: Piotr Swat/Shutterstock AbbVie (NYSE:) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August. ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company’s work in turning Rova-T into a successful lung cancer tr... | AbbVie (ABBV) Source: Piotr Swat/Shutterstock AbbVie (NYSE:) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August. ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company’s work in turning Rova-T into a successful lung cancer tr... | AbbVie (ABBV) Source: Piotr Swat/Shutterstock AbbVie (NYSE:) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August. ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company’s work in turning Rova-T into a successful lung cancer tr... | AbbVie (ABBV) Source: Piotr Swat/Shutterstock AbbVie (NYSE:) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August. ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company’s work in turning Rova-T into a successful lung cancer tr... |
24,891 | 2019-09-08 00:00:00 UTC | 3 Stocks to Buy With Dividends Yielding More Than 6% | ABBV | https://www.nasdaq.com/articles/3-stocks-to-buy-with-dividends-yielding-more-than-6-2019-09-08 | null | null | One definition of yield is to give up something. That definition is important to keep in mind when you're looking at high-yield dividend stocks. Always ask the question: What am I giving up to get that high yield? In some cases, the trade-off of a high-dividend yield is a higher risk that the stock could plunge or that... | AbbVie also recently won U.S. regulatory approvals for two new immunology drugs, Rinvoq and Skyrizi, that are expected to be huge winners. Three stocks I think you can buy right now with dividends yielding more than 6% are AbbVie (NYSE: ABBV), Enterprise Products Partners (NYSE: EPD), and Iron Mountain (NYSE: IRM). Abb... | Three stocks I think you can buy right now with dividends yielding more than 6% are AbbVie (NYSE: ABBV), Enterprise Products Partners (NYSE: EPD), and Iron Mountain (NYSE: IRM). AbbVie AbbVie's dividend currently yields 6.5%. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend payout by an impress... | Three stocks I think you can buy right now with dividends yielding more than 6% are AbbVie (NYSE: ABBV), Enterprise Products Partners (NYSE: EPD), and Iron Mountain (NYSE: IRM). AbbVie AbbVie's dividend currently yields 6.5%. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend payout by an impress... | AbbVie AbbVie's dividend currently yields 6.5%. Three stocks I think you can buy right now with dividends yielding more than 6% are AbbVie (NYSE: ABBV), Enterprise Products Partners (NYSE: EPD), and Iron Mountain (NYSE: IRM). Since being spun off from Abbott in 2013, AbbVie has boosted its dividend payout by an impress... |
24,892 | 2019-09-05 00:00:00 UTC | How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks? | ABBV | https://www.nasdaq.com/articles/how-will-johnson-johnsons-opioid-case-ruling-impact-big-pharma-stocks-2019-09-05 | null | null | August 26 might be the single worst day in 2019 for the pharmaceutical industry. An Oklahoma judge found industry giant Johnson & Johnson (NYSE: JNJ) guilty of deceptively marketing its opioid drugs as being non-addictive despite requests from the U.S. Food and Drug Administration to stop. Currently, there are 2,000 mo... | AbbVie (NYSE: ABBV) is another major pharmaceutical company that stayed out of the opioid industry for the most part and is a suitable candidate for investors fleeing the endangered pharma industry. While the issue has been gaining ground since the early 2000s, this verdict is expected to be a hallmark case for other d... | AbbVie (NYSE: ABBV) is another major pharmaceutical company that stayed out of the opioid industry for the most part and is a suitable candidate for investors fleeing the endangered pharma industry. Even if only a handful of states agree to fine the company the full amount requested by prosecutors, all these settlement... | AbbVie (NYSE: ABBV) is another major pharmaceutical company that stayed out of the opioid industry for the most part and is a suitable candidate for investors fleeing the endangered pharma industry. An Oklahoma judge found industry giant Johnson & Johnson (NYSE: JNJ) guilty of deceptively marketing its opioid drugs as ... | AbbVie (NYSE: ABBV) is another major pharmaceutical company that stayed out of the opioid industry for the most part and is a suitable candidate for investors fleeing the endangered pharma industry. The question pharmaceutical investors need to ask themselves is how big of a deal is this verdict, and which stocks are s... |
24,893 | 2019-09-05 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2019-09-05 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
24,894 | 2019-09-04 00:00:00 UTC | 3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T | ABBV | https://www.nasdaq.com/articles/3-lessons-from-abbvies-%245.8-billion-blunder-with-cancer-drug-rova-t-2019-09-04 | null | null | Turn out the lights. The party's over for Rova-T.
AbbVie (NYSE: ABBV) announced last week that it's completely throwing in the towel on the experimental lung cancer drug after another failure in a late-stage clinical study. The news wasn't a surprise, though: Rova-T was already seen as a lost cause by most observers fo... | The party's over for Rova-T. AbbVie (NYSE: ABBV) announced last week that it's completely throwing in the towel on the experimental lung cancer drug after another failure in a late-stage clinical study. Even shortly after AbbVie acquired Stemcentrx, the small biotech's co-founder and CEO, Brian Slingerland, said in an ... | After all, AbbVie arguably claims the most expertise of any drugmaker when it comes to immunology drugs with its enormously successful track record with Humira. In addition, AbbVie paid an enormously high price tag to buy Stemcentrx. The party's over for Rova-T. AbbVie (NYSE: ABBV) announced last week that it's complet... | When AbbVie acquired Stemcentrx in 2016 for $5.8 billion to get Rova-T, the company's executives were enthusiastic about the potential for the drug to become a huge blockbuster. AbbVie, though, paid $2 billion in cash upfront combined with $3.8 billion in stock for a high-priced small biotech pursuing an approach to fi... | After all, AbbVie arguably claims the most expertise of any drugmaker when it comes to immunology drugs with its enormously successful track record with Humira. But AbbVie's $5.8 billion blunder with Rova-T and its Stemcentrx acquisition underscores the risks associated with investing in biotech stocks. The party's ove... |
24,895 | 2019-09-04 00:00:00 UTC | Nanogold Treatment In The Making For Prostate Cancer | ABBV | https://www.nasdaq.com/articles/nanogold-treatment-in-the-making-for-prostate-cancer-2019-09-04 | null | null | (RTTNews) - Prostate cancer is one of the most common cancers in men. Studies have shown that 1 in 9 men on average, is diagnosed with prostate cancer during his lifetime.
A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within... | A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within the prostate, has yielded positive results. The AuroLase therapy involves intravenous administration of laser-excited gold-silica nanoparticles, called AuroShells. When ex... | (RTTNews) - Prostate cancer is one of the most common cancers in men. Studies have shown that 1 in 9 men on average, is diagnosed with prostate cancer during his lifetime. A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within... | (RTTNews) - Prostate cancer is one of the most common cancers in men. A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within the prostate, has yielded positive results. These AuroShells get accumulated within the solid tumor t... | (RTTNews) - Prostate cancer is one of the most common cancers in men. Studies have shown that 1 in 9 men on average, is diagnosed with prostate cancer during his lifetime. A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within... |
24,896 | 2019-09-01 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy on Sale | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-on-sale-2019-09-01 | null | null | There aren't too many more attractive combinations for income-seeking investors than a high-dividend yield and a bargain price. The bad news is that not many great stocks fit those criteria. The good news, though, is that a few do.
AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim mouthwater... | AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim mouthwatering dividend yields and very attractive valuations. AbbVie AbbVie's dividend currently yields 6.5%. AbbVie remains committed to rewarding shareholders through dividend hikes. | AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim mouthwatering dividend yields and very attractive valuations. AbbVie AbbVie's dividend currently yields 6.5%. AbbVie remains committed to rewarding shareholders through dividend hikes. | See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim mouthwatering dividend yields and very attractive valuations. AbbVie AbbVie's dividend currently yields 6.5%. | AbbVie AbbVie's dividend currently yields 6.5%. AbbVie (NYSE: ABBV), AT&T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim mouthwatering dividend yields and very attractive valuations. AbbVie remains committed to rewarding shareholders through dividend hikes. |
24,897 | 2019-08-30 00:00:00 UTC | Notable ETF Outflow Detected - IXJ, ABBV, LLY, CVS | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-ixj-abbv-lly-cvs-2019-08-30 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $42.6 million dollar outflow -- that's a 2.0% decrease week over week (from 34,900,000 to 34,200,000). Among... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, and CVS Health Corporation (Symbol: CVS) is up by about 0.9%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year ... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, and CVS Health Corporation (Symbol: CVS) is up by about 0.9%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year ... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, and CVS Health Corporation (Symbol: CVS) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, and CVS Health Corporation (Symbol: CVS) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
24,898 | 2019-08-29 00:00:00 UTC | Health Care Sector Update for 08/29/2019: AZN, ABBV, IBIO | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-08-29-2019%3A-azn-abbv-ibio-2019-08-29 | null | null | Top Health Care Stocks:
JNJ: -0.16%
PFE: +0.47%
ABT: +0.93%
MRK: +0.36%
AMGN: -0.04%
Health care stocks were up broadly, including a 0.8% gain for the NYSE Health Care Index in midday trading. Also, shares of health care companies in the S&P 500 were up 0.8% as a group while the Nasdaq Biotechnology Index was ahead 0.5... | Among health care stocks moving on news: (+) AbbVie (ABBV) was edging up 0.3% after it decided to terminate the MERU phase 3 trial evaluating rovalpituzumab tesirine, compared with placebo, as a first-line maintenance therapy for advanced small-cell lung cancer after the drug showed no survival benefit at a pre-planned... | Among health care stocks moving on news: (+) AbbVie (ABBV) was edging up 0.3% after it decided to terminate the MERU phase 3 trial evaluating rovalpituzumab tesirine, compared with placebo, as a first-line maintenance therapy for advanced small-cell lung cancer after the drug showed no survival benefit at a pre-planned... | Among health care stocks moving on news: (+) AbbVie (ABBV) was edging up 0.3% after it decided to terminate the MERU phase 3 trial evaluating rovalpituzumab tesirine, compared with placebo, as a first-line maintenance therapy for advanced small-cell lung cancer after the drug showed no survival benefit at a pre-planned... | Among health care stocks moving on news: (+) AbbVie (ABBV) was edging up 0.3% after it decided to terminate the MERU phase 3 trial evaluating rovalpituzumab tesirine, compared with placebo, as a first-line maintenance therapy for advanced small-cell lung cancer after the drug showed no survival benefit at a pre-planned... |
24,899 | 2019-08-27 00:00:00 UTC | Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong | ABBV | https://www.nasdaq.com/articles/why-jim-cramers-negative-take-on-pfizer-is-flat-out-wrong-2019-08-27 | null | null | I'm not one to bash CNBC Mad Money host Jim Cramer. He's entertaining. He's made some really great calls through the years, notably including his FANG stocks. I thoroughly enjoyed reading Cramer's autobiography, Confessions of a Street Addict, several years ago.
But I think that Jim Cramer's negative take on Pfizer (NY... | But while both Skyrizi and Rinvoq are being evaluated in clinical trials for other indications, AbbVie has already picked up the biggest approvals that it wanted, leaving its pipeline less impressive now. Question-raising comparisons Cramer said that he preferred two other drug stocks above Pfizer -- Merck (NYSE: MRK) ... | Question-raising comparisons Cramer said that he preferred two other drug stocks above Pfizer -- Merck (NYSE: MRK) and AbbVie (NYSE: ABBV). I agree with Cramer that beaten-down AbbVie is a better pick than many investors think. However, AbbVie's biggest challenges for its top-selling drug, Humira, won't come until 2023... | Question-raising comparisons Cramer said that he preferred two other drug stocks above Pfizer -- Merck (NYSE: MRK) and AbbVie (NYSE: ABBV). I agree with Cramer that beaten-down AbbVie is a better pick than many investors think. However, AbbVie's biggest challenges for its top-selling drug, Humira, won't come until 2023... | But while both Skyrizi and Rinvoq are being evaluated in clinical trials for other indications, AbbVie has already picked up the biggest approvals that it wanted, leaving its pipeline less impressive now. Question-raising comparisons Cramer said that he preferred two other drug stocks above Pfizer -- Merck (NYSE: MRK) ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.